Neptune Wellness Solutions (NEPTF) 10-Q 30 Mar 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2022	Mar. 29, 2023
Cover [Abstract]
Entity Registrant Name	NEPTUNE WELLNESS SOLUTIONS INC.
Entity Central Index Key	0001401395
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Small Business	true
Document Type	10-Q
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common shares, no par value
Trading Symbol	NEPT
Security Exchange Name	NASDAQ
Entity File Number	001-33526
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	545 Promenade du Centropolis
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Laval
Entity Address, State or Province	QC
Entity Address, Country	CA
Entity Address, Postal Zip Code	H7T 0A3
City Area Code	450
Local Phone Number	687-2262
Entity Incorporation, State or Country Code	A8
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		11,996,340

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,404,023	$ 8,726,341
Short-term investment	17,540	19,255
Trade and other receivables	4,919,568	7,599,584
Prepaid expenses	2,937,662	3,983,427
Inventories	16,942,808	17,059,406
Total current assets	28,221,601	37,388,013
Property, plant and equipment	1,862,667	21,448,123
Operating lease right-of-use assets	2,144,362	2,295,263
Intangible assets	17,343,178	21,655,035
Goodwill	14,396,380	22,168,288
Total assets	63,968,188	104,954,722
Current liabilities:
Trade and other payables	21,984,254	22,700,849
Current portion of operating lease liabilities	489,849	641,698
Deferred revenues		285,004
Provisions	5,936,933	1,118,613
Liability related to warrants	1,444,058	5,570,530
Total current liabilities	29,855,094	30,316,694
Operating lease liabilities	2,229,583	2,063,421
Loans and borrowings	15,936,658	11,648,320
Other liability	23,000	88,688
Total liabilities	48,044,335	44,117,123
Shareholders' Equity:
Share capital - without par value (11,778,392 shares issued and outstanding as of December 31, 2022;5,560,829 shares issued and outstanding as of March 31, 2022)	321,791,727	317,051,125
Warrants	6,117,600	6,079,890
Additional paid-in capital	57,303,078	55,980,367
Accumulated other comprehensive loss	(14,539,294)	(7,814,163)
Deficit	(357,075,395)	(323,181,697)
Total equity attributable to equity holders of the Company	13,597,716	48,115,522
Non-controlling interest	2,326,137	12,722,077
Total shareholders' equity	15,923,853	60,837,599
Commitments and contingencies
Total liabilities and shareholders' equity	$ 63,968,188	$ 104,954,722

Condensed Consolidated Interi_2

Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2022	Mar. 31, 2022
Statement Of Financial Position [Abstract]
Common shares par value
Common shares issued	11,778,392	5,560,829
Common shares outstanding	11,778,392	5,560,829

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue from sales net of excise taxes of nil and $643,476 (2021 - $746,870 and $1,127,569)	$ 11,945,092	$ 14,371,095	$ 39,668,246	$ 36,502,490
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Royalty revenues	$ 263,816	$ 276,670	$ 766,736	$ 701,330
Other revenues		20,164	32,996	61,249
Total revenues	12,208,908	14,667,929	40,467,978	37,265,069
Cost of sales other than impairment loss on inventories, net of subsidies of nil and nil (2021 - ($3,952) and $927,753 )	(10,328,349)	(13,026,604)	(37,293,901)	(36,109,528)
Impairment gain (loss) on inventories		12,765	(3,079,997)	(2,996,333)
Total Cost of sales	$ (10,328,349)	$ (13,013,839)	$ (40,373,898)	$ (39,105,861)
Cost, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Gross profit (loss)	$ 1,880,559	$ 1,654,090	$ 94,080	$ (1,840,792)
Research and development expenses	(28,836)	(301,645)	(451,121)	(652,421)
Selling, general and administrative expenses, net of subsidies of nil and nil (2021 - ($427)and $100,178 )	(8,727,323)	(18,429,528)	(35,188,695)	(49,902,087)
Impairment loss related to intangible assets			(2,593,529)
Impairment loss related to property, plant and equipment				(2,404,459)
Impairment loss on assets held for sale			(15,346,119)
Impairment loss on right of use assets	(271,057)		(271,057)
Impairment loss related to goodwill			(7,570,471)
Net gain on sale of property, plant and equipment	84,998	6,490	170,000	6,490
Loss from operating activities	(7,061,659)	(17,070,593)	(61,156,912)	(54,793,269)
Finance income		2,956	1,440	10,299
Finance costs	(1,362,776)	(363,466)	(2,658,305)	(1,180,368)
Loss on issuance of derivatives	(1,029,614)		(3,156,569)
Foreign exchange gain (loss)	524,571	(601,347)	6,545,401	(386,865)
Change in revaluation of marketable securities		(17,640)		(107,564)
Gain on revaluation of derivatives	8,367,871	1,245,134	16,083,681	8,706,973
Gain on settlement of liability	66,169		66,169
Nonoperating income (expense)	6,566,221	265,637	16,881,817	7,042,475
Loss before income taxes	(495,438)	(16,804,956)	(44,275,095)	(47,750,794)
Income tax (recovery) expense	(2,013)	50	(14,543)	(11,894)
Net loss	(497,451)	(16,804,906)	(44,289,638)	(47,762,688)
Other comprehensive loss
Net change in unrealized foreign currency gains (losses) on translation of net investments in foreign operations (tax effect of nil for all periods)	(231,490)	332,074	(6,725,131)	(384,432)
Total other comprehensive loss	(231,490)	332,074	(6,725,131)	(384,432)
Total comprehensive loss	(728,941)	(16,472,832)	(51,014,769)	(48,147,120)
Net income (loss) attributable to:
Equity holders of the Company	1,288,110	(15,009,015)	(33,893,698)	(43,029,506)
Non-controlling interest	(1,785,561)	(1,795,891)	(10,395,940)	(4,733,182)
Net loss	(497,451)	(16,804,906)	(44,289,638)	(47,762,688)
Total comprehensive income (loss) attributable to:
Equity holders of the Company	1,056,620	(14,676,941)	(40,618,829)	(43,413,938)
Non-controlling interest	(1,785,561)	(1,795,891)	(10,395,940)	(4,733,182)
Total comprehensive loss	$ (728,941)	$ (16,472,832)	$ (51,014,769)	$ (48,147,120)
Basic income (loss) per share attributable to:
Equity holders of the Company	$ 0.06	$ (3.14)	$ (4.01)	$ (9.03)
Common Shareholders of the Company	0.06	(3.14)	(4.01)	(9.03)
Diluted income (loss) per share attributable to:
Equity holders of the Company	0.06	(3.14)	(4.01)	(9.03)
Common Shareholders of the Company	$ 0.06	$ (3.14)	$ (4.01)	$ (9.03)
Basic weighted average number of common shares	11,030,838	4,781,190	8,462,761	4,765,762
Diluted weighted average number of common shares	11,094,967	4,781,190	8,462,761	4,765,762

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Excise taxes	$ 0	$ 746,870	$ 643,476	$ 1,127,569
Subsidies deducted from cost of sales	0	3,952	0	927,753
Subsidies deducted from selling, general and administrative expenses	$ 0	$ (427)	$ 0	$ 100,178

Condensed Consolidated Interi_5

Condensed Consolidated Interim Statements of Changes in Equity (Unaudited) - USD ($)	Total	Share Capital	Share Capital Direct Offering	Warrants	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Deficit	Equity Attributable to Equity Holders of the Company	Equity Attributable to Non-controlling Interest
Beginning balance at Mar. 31, 2021	$ 137,545,309	$ 306,618,482		$ 5,900,973	$ 59,625,356	$ (8,567,106)	$ (248,209,952)	$ 115,367,753	$ 22,177,556
Beginning balance, shares at Mar. 31, 2021		4,732,090
Net loss for the period	(47,762,688)						(43,029,506)	(43,029,506)	(4,733,182)
Other comprehensive income (loss) for the period	(384,432)					(384,432)		(384,432)
Total comprehensive loss	(48,147,120)					(384,432)	(43,029,506)	(43,413,938)	(4,733,182)
Contributions by and distribution to equity holders
Share-based payment	6,251,713				6,251,713			6,251,713
Warrants in exchange of services rendered by non-employees	178,917			178,917				178,917
RSUs released, net of withholding taxes	(978,699)	$ 6,639,592			(7,618,291)			(978,699)
RSUs released, net of withholding taxes, shares		51,095
Total contributions by and distribution to equity holders	5,451,931	$ 6,639,592		178,917	(1,366,578)			5,451,931
Total contributions by and distribution to equity holders, shares		51,095
Ending balance at Dec. 31, 2021	94,850,120	$ 313,258,074		6,079,890	58,258,778	(8,951,538)	(291,239,458)	77,405,746	17,444,374
Ending balance, shares at Dec. 31, 2021		4,783,185
Beginning balance at Mar. 31, 2021	137,545,309	$ 306,618,482		5,900,973	59,625,356	(8,567,106)	(248,209,952)	115,367,753	22,177,556
Beginning balance, shares at Mar. 31, 2021		4,732,090
Net loss for the period	(84,400,000)
Ending balance at Mar. 31, 2022	60,837,599	$ 317,051,125		6,079,890	55,980,367	(7,814,163)	(323,181,697)	48,115,522	12,722,077
Ending balance, shares at Mar. 31, 2022		5,560,829
Beginning balance at Sep. 30, 2021	110,284,472	$ 312,187,161		6,054,623	58,316,478	(9,283,612)	(276,230,443)	91,044,207	19,240,265
Beginning balance, shares at Sep. 30, 2021		4,779,141
Net loss for the period	(16,804,906)						(15,009,015)	(15,009,015)	(1,795,891)
Other comprehensive income (loss) for the period	332,074					332,074		332,074
Total comprehensive loss	(16,472,832)					332,074	(15,009,015)	(14,676,941)	(1,795,891)
Contributions by and distribution to equity holders
Share-based payment	1,013,795				1,013,795			1,013,795
Warrants in exchange of services rendered by non-employees	25,267			25,267				25,267
RSUs released, net of withholding taxes	(582)	$ 1,070,913			(1,071,495)			(582)
RSUs released, net of withholding taxes, shares		4,044
Total contributions by and distribution to equity holders	1,038,480	$ 1,070,913		25,267	(57,700)			1,038,480
Total contributions by and distribution to equity holders, shares		4,044
Ending balance at Dec. 31, 2021	94,850,120	$ 313,258,074		6,079,890	58,258,778	(8,951,538)	(291,239,458)	77,405,746	17,444,374
Ending balance, shares at Dec. 31, 2021		4,783,185
Beginning balance at Mar. 31, 2022	60,837,599	$ 317,051,125		6,079,890	55,980,367	(7,814,163)	(323,181,697)	48,115,522	12,722,077
Beginning balance, shares at Mar. 31, 2022		5,560,829
Net loss for the period	(44,289,638)						(33,893,698)	(33,893,698)	(10,395,940)
Other comprehensive income (loss) for the period	(6,725,131)					(6,725,131)		(6,725,131)
Total comprehensive loss	(51,014,769)					(6,725,131)	(33,893,698)	(40,618,829)	(10,395,940)
Contributions by and distribution to equity holders
Share-based payment	2,832,438				2,832,438			2,832,438
Common shares issued in connection with debt financing	645,921	$ 645,921						645,921
Common shares issued in connection with debt financing (shares)		409,435
Warrants reclassified from liability	37,710			37,710				37,710
Warrants exercised	1,769,000	$ 1,769,000						1,769,000
Warrants exercised (shares)		384,446
RSUs released, net of withholding taxes	815,954	$ 2,325,681			(1,509,727)			815,954
RSUs released, net of withholding taxes, shares		269,599
Shares issued during period, shares			5,154,083
Total contributions by and distribution to equity holders	6,101,023	$ 4,740,602		37,710	1,322,711			6,101,023
Total contributions by and distribution to equity holders, shares		6,217,563
Ending balance at Dec. 31, 2022	15,923,853	$ 321,791,727		6,117,600	57,303,078	(14,539,294)	(357,075,395)	13,597,716	2,326,137
Ending balance, shares at Dec. 31, 2022		11,778,392
Beginning balance at Sep. 30, 2022	15,596,395	$ 321,769,905		6,079,890	56,306,211	(14,307,804)	(358,363,505)	11,484,697	4,111,698
Beginning balance, shares at Sep. 30, 2022		8,516,894
Net loss for the period	(497,451)						1,288,110	1,288,110	(1,785,561)
Other comprehensive income (loss) for the period	(231,490)					(231,490)		(231,490)
Total comprehensive loss	(728,941)					(231,490)	1,288,110	1,056,620	(1,785,561)
Contributions by and distribution to equity holders
Share-based payment	1,005,455				1,005,455			1,005,455
Warrants reclassified from liability	37,710			37,710				37,710
RSUs released, net of withholding taxes	13,234	$ 21,822			(8,588)			13,234
RSUs released, net of withholding taxes, shares		52,941
Shares issued during period, shares			3,208,557
Total contributions by and distribution to equity holders	1,056,399	$ 21,822		37,710	996,867			1,056,399
Total contributions by and distribution to equity holders, shares		3,261,498
Ending balance at Dec. 31, 2022	$ 15,923,853	$ 321,791,727		$ 6,117,600	$ 57,303,078	$ (14,539,294)	$ (357,075,395)	$ 13,597,716	$ 2,326,137
Ending balance, shares at Dec. 31, 2022		11,778,392

Condensed Consolidated Interi_6

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (497,451)	$ (16,804,906)	$ (44,289,638)	$ (47,762,688)	$ (84,400,000)
Adjustments:
Depreciation of property, plant and equipment			652,196	2,135,961
Non-cash lease expense			385,800	563,428
Amortization of intangible assets			1,352,787	2,436,219
Impairment loss on goodwill			7,570,471
Share-based payment			2,832,438	6,251,713
Impairment loss on inventories	0	2,996,333	3,079,997	2,996,333
Expected credit losses			496,846	1,978,705
Non-employee compensation related to warrants				178,917
Loss on issuance of derivatives	1,029,614		3,156,569
Net finance expense			2,656,865	1,170,069
Unrealized foreign exchange (gain) loss			(6,545,401)	10,568
Change in revaluation of marketable securities		17,640		107,564
Interest received			1,440	7,796
Interest paid			(215,019)	(961,463)
Gain on settlement of liability	(66,169)		(66,169)
Revaluation of derivatives			(16,083,681)	(8,706,973)
Impairment loss on property, plant and equipment				2,404,459
Impairment loss on assets held for sale			15,346,119
Impairment loss on right-of-use assets	271,057		271,057
Impairment loss on intangibles			2,593,529
Payment of lease liabilities			(253,795)	(236,802)
Income tax expense	2,013	(50)	14,543	11,894
Net gains from sale of property, plant and equipment	(84,998)	(6,490)	(170,000)	(6,490)
Changes in operating assets and liabilities			6,543,514	(6,394,409)
Income taxes paid			(360)	(11,894)
Net cash used in operating activities			(20,669,892)	(43,820,603)	(54,300,000)
Cash flows from investing activities:
Proceeds on sale of assets			170,000
Proceeds from the sale of Cannabis assets			3,121,778
Acquisition of property, plant and equipment			(601,743)	(1,034,982)
Acquisition of intangible assets				(434,168)
Sales of Acasti shares				44,509
Net cash provided by (used in) investing activities:			2,690,035	(1,424,641)
Cash flows from financing activities:
Increase in loans and borrowings, net of financing fees			3,800,000
Withholding taxes paid pursuant to the settlement of non-treasury RSUs			(574,153)	(978,699)
Warrants issuance costs			(1,330,211)
Proceeds from exercise of options and pre-funded warrants			65
Net cash provided by (used in) financing activities:			12,895,705	(978,699)
Foreign exchange loss on cash and cash equivalents			(238,166)	(454,341)
Net increase (decrease) in cash and cash equivalents			(5,322,318)	(46,678,284)
Cash and cash equivalents, beginning of period			8,726,341	59,836,889	59,836,889
Cash and cash equivalents as at December 31, 2022 and 2021	3,404,023	13,158,605	3,404,023	13,158,605	$ 8,726,341
Cash and cash equivalents is comprised of:
Cash	$ 3,404,023	$ 13,158,605	3,404,023	13,158,605
Changes in operating assets and liabilities:
Trade and other receivables			2,489,793	(2,541,426)
Prepaid expenses			798,493	(2,162,076)
Inventories			(2,544,635)	(2,720,569)
Trade and other payables			1,599,623	2,684,869
Deferred revenues			(285,006)	(303,765)
Provisions			4,550,934	(1,112,762)
Other liabilities			(65,688)	(238,680)
Changes in operating assets and liabilities			6,543,514	$ (6,394,409)
Direct Offering [Member]
Cash flows from financing activities:
Proceeds from the issuance of shares and warrants			5,000,002
Registered Direct Offering Priced At The Market And Concurrent Private Placement [Member]
Cash flows from financing activities:
Proceeds from the issuance of shares and warrants			$ 6,000,002

Reporting Entity

Reporting Entity	9 Months Ended
	Dec. 31, 2022
Reporting Entity [Abstract]
Reporting entity	1. Reporting entity : Neptune Wellness Solutions Inc. (the "Company" or "Neptune") is incorporated under the Business Corporations Act (Québec) (formerly Part 1A of the Companies Act (Québec)). The Company is domiciled in Canada and its registered office is located at 100-545 Promenade du Centropolis, Laval, Québec. The condensed consolidated interim financial statements of the Company comprise the Company and its subsidiaries, Biodroga Nutraceuticals Inc. ("Biodroga"), SugarLeaf Labs, Inc. ("SugarLeaf"), 9354-7537 Québec Inc., Neptune Holding USA, Inc., Neptune Health & Wellness Innovation, Inc., Neptune Forest, Inc., Neptune Care, Inc. (formerly known as Neptune Ocean, Inc.), Neptune Growth Ventures, Inc., 9418-1252 Québec Inc., Neptune Wellness Brands Canada, Inc. and Sprout Foods, Inc. (“Sprout”). All subsidiaries are wholly-owned, except for Sprout for which the Company has a 50.1 % interest. Neptune is a diversified and fully integrated health and wellness company. Through its flagship consumer-facing brands, Neptune Wellness, Forest Remedies™, Biodroga, MaxSimil®, Sprout®, Nosh® and NurturMe®, Neptune is redefining health and wellness by building a broad portfolio of natural, plant-based, sustainable and purpose-driven lifestyle brands and consumer packaged goods products in key health and wellness markets, including nutraceuticals, organic baby food, personal care and home care. On June 8, 2022, Neptune announced the launch of a new Consumer Packaged Goods ("CPG") focused strategic plan to reduce costs, improve the Company's path to profitability and enhance current shareholder value. This plan builds on the Company's initial strategic review that took place in fall of 2021 and focuses on two primary actions: (1) the divestiture of the Company's Canadian cannabis business and (2) a realignment of focus and operational resources toward increasing the value of Neptune's CPG business. Sale of Cannabis Assets On October 17, 2022, Neptune announced an agreement to sell substantially all of its Cannabis assets (including, but not limited to, the production facility located in Sherbrooke, Québec and certain legal entities including various related brand names and trademarks, including MoodRing and PanHash) to PurCann Pharma Inc. These assets were reported as Assets Held For Sale ("AHFS") as of September 30, 2022. On November 9, 2022 the sale to PurCann Pharma Inc. was completed. Share consolidation and delisting from TSX On June 9, 2022, Neptune announced the completion of the Company's proposed consolidation of its common shares (the "Common Shares") on the basis of one (1) post-consolidation Common Share for every thirty-five (35) pre-consolidation Common Shares (the "Share Consolidation"). The post-consolidation Common Shares commenced trading on the NASDAQ and the TSX at the market open on June 13, 2022. The Share Consolidation reduced the number of Common Shares issued and outstanding from approximately 198 million Common Shares to approximately 5.7 million Common Shares as at June 13, 2022. These consolidated financial statements have been retroactively adjusted to reflect the Share Consolidation. As a result, the number of common shares, options, deferred share units ("DSUs"), restricted share units ("RSUs"), restricted shares and warrants, issuance and exercise prices of options, DSUs, RSUs, restricted shares and warrants, loss per share reflect the Share Consolidation. On July 29, 2022, Neptune announced that it has applied and received approval for a voluntary delisting of its common shares from the Toronto Stock Exchange ("TSX"). The delisting from the TSX will not affect the Company's listing on the Nasdaq Capital Market ("Nasdaq"). Neptune's common shares were delisted from the TSX at the close of trading on August 15, 2022. Going concern 44.3 million and negative cash flows from operations of $ 20.7 million , and had an accumulated deficit of $ 357.1 million as of December 31, 2022 . For the year ended March 31, 2022, the Company incurred a net loss of $ 84.4 million and negative cash flows from operations of $ 54.3 million. Furthermore, as at December 31, 2022, the Company’s current liabilities and expected level of expenses for the next twelve months exceed cash on hand of $ 3.4 million and its total current liabilities exceed its total current assets. Accordingly, the Company is required to actively manage its liquidity and expenses and payments of payables are not being made as the amounts become due for certain suppliers. The Company currently has no committed sources of financing available other than from the transactions completed after period-end from the debt financing and the accounts receivable factoring facility (see note 18). As of the date these financial statements are authorized for issuance, the cash balance is expected to be sufficient to operate the business for the next one to two months under the current business plan. The Company requires funding in the very near term in order to continue its operations. If the Company is unable to obtain funding in the near-term, it may have to cease operations and liquidate its assets. These conditions cast substantial doubt about the Company's ability to continue as a going concern. Going forward, the Company will seek additional financing in various forms. To achieve the objectives of its business plan, Neptune plans to raise the necessary funds through additional securities offerings and the establishment of strategic alliances. The ability of the Company to complete the needed financing and ultimately achieve profitable operations is dependent on a number of factors outside of the Company’s control. The Company’s business plan is dependent upon, among other things, its ability to achieve and maintain profitability, continue to obtain adequate ongoing debt and/or equity financing to finance operations within and beyond the next twelve months. See note 18 regarding a new debt issuance in January 2023 and related waiver. While the Company has been successful in obtaining financing from public issuances and private placements, there is no certainty as to future financings. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the going concern basis not be valid. These adjustments could be material.

Basis of Preparation

Basis of Preparation	9 Months Ended
	Dec. 31, 2022
Disclosure Of Basis Of Preparation [Abstract]
Basis of preparation	2. Basis of preparation: (a) Adoption of U.S. GAAP: As at March 31, 2022, the Company retroactively adopted United States generally accepted accounting principles (“US GAAP”). The consolidated financial statements of the Company have been prepared in accordance with US GAAP for all periods presented. Comparative figures, which were previously prepared in accordance with International Financial Reporting Standards (”IFRS”) as issued by the International Accounting Standards Board, have been adjusted as required to be compliant with the Company’s accounting policies under US GAAP. (b) Functional and reporting currency: Effective March 31, 2022, the Company changed its reporting currency from Canadian dollars (“CAD”) to U.S. dollars (“USD”). This change in reporting currency has been applied retroactively such that all amounts in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in U.S. dollars. References to "$" and "USD" are U.S dollars and references to “CAD $” and "CAD" are to Canadian dollars. For comparative purposes, historical consolidated financial statements were recast in U.S. dollars by translating (i) assets and liabilities at the closing exchange rate in effect at the end of the respective period, (ii) revenues, expenses and cash flows at the average exchange rate in effect for the respective period and (iii) equity transactions at historical exchange rates. Translation gains and losses are included as part of the cumulative foreign currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss. The assets and liabilities of foreign operations with a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate in effect at the balance sheet date. Revenue and expenses are translated at the monthly average exchange rates for the period. Differences arising from the exchange rate changes are recorded within foreign currency translation adjustments, a component of other comprehensive income (loss). Transactions in foreign currencies are translated to the respective functional currencies of the Company’s subsidiaries at the average exchange rates for the period. The monetary items denominated in currencies other than the functional currency of a subsidiary are translated at the exchange rates prevailing at the balance sheet date. Non-monetary items denominated in currencies other than the functional currency are translated at historical rates. Gains and losses resulting from re-measurement are recorded in the Company’s consolidated statement of loss as foreign exchange gain (loss). As a result of the divesture of its Canadian cannabis business, a significant portion of its remaining revenues, expenses, assets and liabilities are denominated in US dollars. In addition and as a result of the increasing operations in the U.S., Neptune changed its functional currency from Canadian dollars (“CAD”) to U.S. dollars (“USD”), effective October 1, 2022. This change in functional currency has been applied prospectively from the date of the change. All assets and liabilities were reported using the same USD values as previously reported under the USD reporting currency described above. The cumulative translation account in Neptune was effectively frozen and the accumulated balance as at September 30, 2022 is carried forward. Changes in the cumulative translation account after October 1, 2022 relate to conversion of subsidiary financial statements whose functional currency is not USD. As of October 1, 2022, the 2020 Warrants and 2021 Warrants no longer met the criteria for liability classification and therefore were reclassified to equity on this date (see note 10(f)). (c) Use of estimates: The preparation of the condensed consolidated interim financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from the estimates made by management. Estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Estimates include the following: • Estimating the write down of inventory. • Estimating expected credit losses for receivables. • Estimating the recoverable amount of non-financial assets, to determine and measure impairment losses on goodwill, intangibles, and property, plant and equipment. • Estimating the lease term of contracts with extension options and termination options. • Estimating the revenue from contracts with customers subject to variable consideration. • Estimating the fair value of bonus, options and warrants that are based on market and non-market conditions (note 12). • Estimating the fair value of the identifiable assets acquired, liabilities assumed, and consideration transferred of the acquired business, including the related contingent consideration and call option. • Estimating the litigation provision as it depends upon the outcome of proceedings (note 7). (d) Assets held for sale: On June 8, 2022, the Company announced a planned divestiture of the Canadian cannabis business and that the Company would focus on winding up its cannabis operations pending one or more sales transactions. Following this announcement, the Canadian cannabis disposal group assets met the criteria to be classified as held for sale. At September 30, 2022, the disposal group had been measured at fair value less cost to sell and impaired to reflect the asset sale and purchase agreement (the "ASPA") signed with a third-party on October 16, 2022 for $ 3,790,340 ($ 5,150,000 CAD), with cost to sell the Canadian cannabis disposal group asset in the amount of $ 586,783 , for net assets held for sale of $ 3,203,557 , resulting in impairment losses o f nil and $ 15,346,119 respectively for the three and nine-month periods ended December 31, 2022. The transaction closed on November 9, 2022.

Significant accounting policies

Significant accounting policies	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Significant accounting policies	3. Significant accounting policies: These unaudited Consolidated Interim Financial Statements have been prepared in accordance U.S. GAAP and on a basis consistent with those accounting principles followed by the Company and disclosed in note 2 of its Annual Consolidated Financial Statements for the year ended March 31, 2022, (except as disclosed in note 3(c) to these financial statements) and should be read in conjunction with and Notes thereto. (a) Basis of consolidation: These consolidated financial statements include the accounts of the Company and its subsidiaries in which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated from the Company’s consolidated financial statements. On February 10, 2021, Neptune acquired a 50.1 % interest in Sprout Foods, Inc. (“Sprout” or “Sprout Foods”). The accounts of the subsidiary are included in the consolidated financial statements from that date. (b) New standards and interpretations not yet adopted: Accounting pronouncements not yet adopted In October 2021, the FASB issued ASU 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which amends ASC Topic 805, Business Combinations, ASU 2021-18 improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to the (1) recognition of an acquired contract liability and (2) payment terms and their direct effect on subsequent revenue recognized by the acquirer. ASU 2021-08 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2022. Management has not yet evaluated the impact of this ASU on the Company's consolidated financial statements and the Company does not intend to adopt ASU 2021-18 until its fiscal year beginning April 1, 2023. In June 2016, the FASB issued ASU 2016-13, Financial instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the guidance on the impairment of financial instruments by requiring measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, and earlier adoption is permitted beginning in the first quarter of fiscal 2019. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will still have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. The Company will adopt ASU 2016-13 for its fiscal year beginning April 1, 2023, and the Company’s evaluation of the potential impact of adoption is in process. (c) Assets held for sale: The Company classifies long-lived assets or disposal groups to be sold as assets held for sale in the period in which all of the following conditions are met: management, having the authority to approve the action, commits to a plan to sell the asset or disposal group; the asset or disposal group is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets or disposal groups; an active program to locate a buyer and other actions required to complete the plan to sell the asset or disposal group have been initiated; the sale of the asset or disposal group is probable, and transfer of the asset or disposal group is expected to qualify for recognition of a completed sale within one year; the assets of disposal group are subject to an asset sale and purchase agreement (see notes 2(d)); and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Assets and liabilities directly associated with assets held for sale are measured at the lower of carrying amount and fair value less costs to sell immediately prior to their classification. Any loss resulting from this measurement is recognized in the period in which the held-for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of the sale. Assets classified as held for sale, and the assets and liabilities included within the disposal group classified as held for sale are presented separately on the face of the balance sheet. Non-current assets that are classified as held for sale are not depreciated.

Inventories

Inventories	9 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	4. Inventories: December 31, March 31, Raw materials $ 5,154,170 $ 7,920,190 Work in progress — 1,016,916 Finished goods 11,433,593 7,974,690 Supplies and spare parts 355,045 147,610 $ 16,942,808 $ 17,059,406 During the three and nine-month periods ended December 31, 2022, the Company recorded impairment losses of nil and $ 3,079,997 respectively (2021 – impairment losses of $ 2,996,333 and $ 2,996,333 , respectively) as a result of inventory measurements to their net realizable value. The impairment loss during the nine-month period ended December 31, 2022 is related to cannabis inventories that were impaired because they were subsequently sold or expected to be sold at prices lower than costs.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Dec. 31, 2022
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	5. Property, plant and equipment: As at September 30, 2022, property, plant and equipment related to the Canadian cannabis asset group were classified as assets held for sale on the balance sheet (refer to note 2(d)). As indicated in note 2(d), the Cannabis related assets were written down, resulting in impairment losses of nil and $ 15,346,119 respectively for the three and nine-month periods ended December 31, 2022. During the three-month and nine-month period ended December 31, 2021 the Company recognized impairment losses of nil and $ 2,404,459 , respectively. The Company impaired certain equipment of the Canadian cannabis long-lived assets to nil resulting in an impairment charge of $ 1,424,517 for the nine-month period ended December 31, 2021 and an impairment reversal gain of $ 10,243 for the three-month period ended December 31, 2021 . In addition, the Company impaired the long-lived assets of the SugarLeaf reporting unit as they were no longer generating economic benefits. The fair value of these long-lived assets was established to be nil and as such an impairment charge of $ 979,942 was recorded during the nine-month period ended December 31, 2021 .

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Dec. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and intangible assets: The Company assesses at each reporting date whether there is an indication that an asset group or a reporting unit may be impaired. In the third quarter of 2022 due to the Company’s sustained decrease in share price, the Company concluded a triggering event occurred and performed a quantitative impairment test for the Sprout reporting unit. As part of the impairment testing process, the Company considered a number of factors including, but not limited to, current macroeconomic conditions such as inflation, economic growth, and interest rate movements, industry and market considerations, stock price performance (including performance relative to peers) and overall financial performance of the Sprout reporting unit. Although management used its best estimate to assess the potential impact of the changes in the general economic conditions on the Company’s business, management exercised significant judgment to estimate forecasted cash flows and discount rate, using assumptions which are subject to significant uncertainties. Based on the results of the Company’s third quarter 2022 impairment analysis, the estimated fair value of the Sprout reporting unit exceeded its carrying value, and no impairment was recognized. During the second quarter of 2022, there were changes in the general economic and financial conditions of the markets the Company serves. The Company’s Sprout reporting unit was adversely impacted during the second quarter of 2022 by these conditions, which impacted the operating results. Accordingly, management concluded that these factors were indicators of impairment. As a result, management performed an impairment test for the Sprout reporting unit, for which it revised its assumptions on projected earnings and cash flows growth, as well as its assumptions on discount rates used to apply to the forecasted cash flows, using its best estimate of the conditions existing at September 30, 2022. Although management used its best estimate to assess the potential impact of the changes in the general economic conditions on the Company’s business, management exercised significant judgment to estimate forecasted cash flows and discount rate, using assumptions which are subject to significant uncertainties. Accordingly, differences in estimates could affect whether a reporting unit is impaired and the dollar amount of that impairment, which could be material. The Company compared the carrying amount of the reporting unit to the fair value. The fair value of the Sprout reporting unit was determined to be lower than the carrying value and a $ 7,570,471 goodwill impairment expense was recorded in the quarter ended September 30, 2022. The fair value of the reporting unit was estimated using a discounted cash flow model with a WACC post-tax discount rate of 11.0 % and a market multiples valuation approach. The discount rate represents the risk adjusted WACC of the reporting unit, based on publicly available information and that of comparable companies operating in similar industries. Determination of the WACC requires separate analysis of the cost of equity and debt, and considers a risk premium based on an assessment of risks related to the projected cash flows of the reporting unit. Cash flows were projected based on past experience, actual operating results and the three-year business plan including a terminal growt h rate of 3.5 % . The most significant assumptions used to estimate the fair values using a discounted cash flow model included the forecasted revenue, gross margins, net working capital investment, terminal value as well as the discount rate. These significant assumptions are classified as Level 3 in the fair value hierarchy, signifying that they are not based on observable market data. A decrease in the projected cash flow or an increase in discount rate could have resulted in a higher impairment charge. Should these projections not be realized, or the discount rate needs to be increased, an impairment loss may be needed in future periods. Due to the impairment losses recorded during the second quarter of 2023, there is no headroom between the fair value of the reporting unit and its carrying value and therefore, changes in assumptions in future periods may result in additional impairment charges. The aggregate amount of goodwill is allocated to each reporting unit as follows: December 31, March 31, Biodroga $ 2,424,414 $ 2,625,851 Sprout 11,971,966 19,542,437 $ 14,396,380 $ 22,168,288 The Company also identified a trigger of impairment related to its intangible assets and recorded impairment charges of nil and $ 2,593,529 respectively for Sprout trademarks during the three and six-month periods ended September 30, 2022. The fair value was determined using a relief from royalty discounted cash flow model.

Provisions

Provisions	9 Months Ended
	Dec. 31, 2022
Disclosure Of Provisions [Abstract]
Provisions	7. Provisions (a) During the year ended March 31, 2019, the Company received a judgment from the Superior Court of Québec (the “Court”) in respect of certain royalty payments alleged to be owed and owing to a former chief executive officer of the Company (the “Former CEO”) pursuant to the terms of an agreement entered into on February 23, 2001 between Neptune and the Former CEO (the “Royalty Agreement”). The Company appealed the judgment which was dismissed by the Court of Appeal of Québec in February 2021. Under the terms of the Royalty Agreement and as maintained by the court, annual royalties of 1 % of the sales and other revenue made by the Company on a consolidated basis are payable by the Company to the Former CEO biannually, but only to the extent that the cost of the royalty would not cause the Company to have a loss before interest, taxes and amortization (in which case, the payments would be deferred to the following fiscal year). As of December 31, 2022, a provision of $ 606,346 (March 31, 2022 - $ 362,809 ) has been recorded by the Company. During the three and nine-month periods ended December 31, 2022, the Company increased the provision by $ 64,415 and $ 281,244 respectively, recorded foreign currency translation adjustments of $ 9,317 and $ ( 37,707 ) respectively, and made no payments to the Former CEO in relation to this provision. During the three and nine-month periods ended December 31, 2021, the Company increased the provision by $ 135,757 and $ 651,229 respectively, recorded foreign currency translation adjustments of $ ( 6,061 ) and $ 3,750 respectively, and made payments totaling $ 7,515 and $ 1,763,991 respectively to the Former CEO in relation to this provision. Effective as of September 20, 2022, the Company notified the Former CEO that it was exercising its legal rights to terminate the Royalty Agreement. In response to such termination, the Former CEO is seeking a declaratory judgment that the Company did not have the legal right to terminate the Royalty Agreement. (b) In September 2020, Neptune submitted a claim and demand for arbitration against Peter M. Galloway and PMGSL Holdings, LLC (collectively “PMGSL”) in accordance with the SugarLeaf Asset Purchase Agreement (“APA”) dated May 9, 2019 between Neptune, PMGSL, Peter M. Galloway and Neptune Holding USA, Inc. Separately, PMGSL submitted a claim and demand for arbitration against Neptune. The Neptune claims and PMGSL claims have been consolidated into a single arbitration and each are related to the purchase by Neptune of substantially all of the assets of the predecessor entities of PMGSL Holdings, LLC. Neptune is claiming, among other things, breach of contract and negligent misrepresentation by PMGSL in connection with the APA and is seeking, among other things, equitable restitution and any and all damages recoverable under law. PMGSL is claiming, among other things, breach of contract by Neptune and is seeking, among other things, payment of certain compensation contemplated by the APA. A merit hearing in the arbitration took place in April 2022 and August 1, 2022. While Neptune believes there is no merit to the claims brought by PMGSL, a judgment in favor of PMGSL may have a material adverse effect on our business and Neptune intends to continue vigorously defending itself. Based on currently available information, a provision of $ 600,000 has been recognized for this case as at December 31, 2022 ($ 600,000 as at March 31, 2022). (c) A supplier of cannabis initiated a lawsuit against the Company's subsidiary, 9354-7537 Quebec Inc., ("9354") for breach of a Wholesale Cannabis Supply Agreement (the “Supply Agreement”) for the purchase of cannabis trim. The purchased trim was rejected by 9354 due to quality concerns. The supplier refused to refund the purchase price and ultimately sued 9354 for breach of the Supply Agreement. The matter proceeded to trial in November 2021, and on March 23, 2022, an arbitrator entered an arbitration award against 9354 for the full purchase price of the trim. With fees and costs, the final arbitrator’s award entered against 9354 was $ 1,127,024 , plus applicable interest. During the quarter ended June 30, 2022, the parties engaged into settlement negotiations which resulted in the execution of a settlement agreement dated July 13, 2022 . As at June 30, 2022, the payable was revised to the settlement amount of $ 543,774 which resulted in the recognition of a settlement gain of $ 583,430 under Selling, general and administrative expenses for the three-month period ended June 30, 2022. During the three-month period ended September 30, 2022, the Company made a payment of $ 187,025 to the supplier, and recorded foreign currency translation adjustments of $ ( 12,496 ) . This provision was included in trade and other payables. The Company made the final payment on October 12, 2022. As at December 31, 2022 , the balance of this payable was nil . (d) On March 16, 2021, a purported shareholder class action was filed in United States District Court for the Eastern District of New York against the Company and certain of its current and former officers alleging violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934, with respect to the Company’s acquisition of SugarLeaf Labs, Inc. On October 21, 2022, the Company announced that it had agreed to settle and resolve the purported shareholder class action for a gross payment to the class of between $ 4 and $ 4.25 million, with the exact amount being within the Company’s control and dependent on the type of consideration used. The settlement was subject to court approval and certification by the court of the class. On March 16, 2023 the settlement offer was accepted and the first payment in the amount of $ 500,000 was paid on March 22, 2023. Two additional payments of $ 500,000 each are due 30 days and 60 days after the first payment. The rest is payable either in cash ($ 2,500,000 ) or in shares ($ 2,750,000 ) at Neptune's election, within 31 days after the Final Approval Order is entered. As of December 31, 2022, a provision and an expense within selling, general administration of $ 4,000,000 (March 31, 2022 - nil ) has been recorded by the Company. (e) As at December 31, 2022, the Company has various additional other provisions for legal fees obligations for an aggregate amount of $ 730,587 (March 31, 2022 – $ 155,804 ).

Liability Related to Warrants

Liability Related to Warrants	9 Months Ended
	Dec. 31, 2022
Warrants And Rights Note Disclosure [Abstract]
Liability Related to Warrants	8. Liability related to warrants: The Company has issued common shares, pre-funded warrants and warrants as part of its financing arrangements which are exercisable for a variable number of shares. Common shares and pre-funded warrants are classified as equity. Warrants are classified as liabilities rather than equity. As of October 1, 2022, as a result of the change in functional currency of Neptune, the 2020 Warrants and 2021 Warrants no longer met the criteria for liability classification and therefore were reclassified as equity prospectively (see note10(f)). On October 11, 2022, the Company closed a registered direct offering ("October 2022 Direct Offering") of 3,208,557 of its Common Shares and warrants ("Series E Warrants") to purchase up to 6,417,114 Common Shares in the concurrent Private Placement. The combined purchase price for one Common Share and one warrant was $ 1.87 . The Series E Warrants have an exercise price of $ 1.62 per Common Share, are exercisable immediately following the date of issuance and will expire five years from the date of issuance. The Company received gross proceeds of $ 6,000,002 and net proceeds of $ 5,135,002 after deducting the placement agent fees and expenses, and the Company’s offering expenses. Based on the fair value of the warrants as at the date of closing, which was determined using a Black-Scholes model, the Company recorded the full proceeds to liabilities, with an initial liability of $ 7,029,614 and a loss on initial recognition of $ 1,029,614 . Because the fair value of the liability classified warrant exceeded the total proceeds, no consideration was allocated to the Common Shares. Total issue costs related to this offering of $ 865,000 were recorded under finance costs. On June 23, 2022, Neptune issued a total of 645,526 pre-funded warrants (“Pre-Funded Warrants”), along with 1,300,000 common shares of the Company, as part of a registered direct offering ("June 2022 Direct Offering"). Each Pre-Funded Warrant was exercisable for one Common Share. The common shares and the Pre-Funded Warrants were sold together with 1,945,526 Series C Warrants (the "Series C Warrants"), and 1,945,526 Series D Warrants (the "Series D Warrants") and collectively, the "June 2022 Common Warrants". Each of the June 2022 Common Warrant is exercisable for one common share. Each of the common share and Pre-Funded Warrants and the accompanying June 2022 Common Warrants were sold together at a combined offering price of $ 2.57 , for aggregate gross proceeds of $ 5,000,002 before deducting fees and other estimated offering expenses. The Pre-Funded Warrants are funded in full at closing except for a nominal exercise price of $ 0.0001 and are exercisable commencing on the Closing Date and will terminate when such Pre-Funded Warrants are exercised in full. The Series C Warrants and the Series D Warrants have an exercise price of $ 2.32 per share and can be exercised for a period of 5 years and 2 years respectively from the date of issuance. On October 6, 2022, the Company agreed to extend the termination date of 972,763 Series C Warrants by two years . Proceeds of the June 2022 Direct Offering were allocated between common shares and warrants first by allocating proceeds to the warrants classified as a liability based on their fair value and then allocating the residual to the equity instruments, which includes the Pre-Funded Warrants. The fair value of the liability-classified warrants was determined using the Black-Scholes model, resulting in an initial warrant liability of $ 4,046,836 for the Series C Warrants and $ 3,080,121 for the Series D Warrants. Because the fair value of the liability classified warrant exceeded the total proceeds, no consideration was allocated to the Common Shares and Pre-Funded Warrants and a loss $ 2,126,955 w as immediately recognized in the net loss of the period as there were no additional rights or privileges identified. The Company is in need of financing to be able to continue its activities as described in note 1. The Pre-Funded Warrants were exercised in full on June 24, 2022 for gross proceeds of $ 65 . Total issue costs related to this private placement of $ 465,211 , were recorded under finance costs. During the month of August 2022, a total of 201,207 Series C Warrants and 972,763 Series D Warrants were exercised at $ 2.32 each in cashless transactions, which resulted in an aggregate total of 384,446 shares being issued for an aggregate value of $ 1,769,000 . The fair value of the Series C Warrants and Series D Warrants liability was determined using the Black-Scholes model. Warrants are revalued each period-end at fair value and accounted for in the Company's profit and loss statement under “gain on revaluation of derivatives”. Changes in the value of the liability related to the warrants for the nine-month period ended December 31, 2022 and 2021 were as follows: Warrants Amount Outstanding as at March 31, 2021 497,355 $ 10,462,137 Revaluation ( 8,853,111 ) Movements in exchange rates 32,916 Outstanding as at December 31, 2021 497,355 1,641,942 Outstanding as at March 31, 2022 1,925,929 $ 5,570,530 Warrants issued during the period 10,308,166 14,156,571 Warrants exercised during the period ( 1,173,970 ) ( 1,769,000 ) Warrants reclassified to equity during the period ( 497,355 ) ( 37,710 ) Revaluation gain ( 16,083,681 ) Movements in exchange rates ( 392,652 ) Outstanding as at December 31, 2022 10,562,770 1,444,058 The following table provides the relevant information on the outstanding warrants as at December 31, 2022: Reference Date of issuance Number of warrants outstanding Number of warrants exercisable Exercise price Expiry date Series A Warrants March 14, 2022 714,287 714,287 $ 11.20 September 14, 2027 Series B Warrants March 14, 2022 714,287 714,287 $ 11.20 March 14, 2028 Series C Warrants June 23, 2022 771,556 771,556 $ 2.32 June 23, 2027 Series C Warrants June 23, 2022 972,763 972,763 $ 2.32 June 23, 2029 Series D Warrants June 23, 2022 972,763 972,763 $ 2.32 June 24, 2024 Series E Warrants October 11, 2022 6,417,114 6,417,114 $ 1.62 October 11, 2027 10,562,770 10,562,770 $ 3.10 The holders of warrants listed above will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares. The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value for the respective nine-month periods is presented in the following tables: 2020 Warrants 2021 Warrants December 31, December 31, December 31, December 31, Balance - beginning of period $ 309,769 $ 6,174,137 $ 306,704 $ 4,288,000 Warrants reclassified to equity during the period ( 19,058 ) — ( 18,652 ) — Change in fair value to date of transfer to equity ( 279,056 ) ( 5,300,014 ) ( 276,527 ) ( 3,553,097 ) Translation effect ( 11,655 ) 20,701 ( 11,525 ) 12,215 Balance - end of period $— $ 894,824 $— $ 747,118 Series A Warrants Series B Warrants December 31, December 31, December 31, December 31, Balance - beginning of period $ 3,270,816 $— $ 1,683,241 $— Change in fair value ( 3,099,783 ) — ( 1,622,926 ) — Translation effect ( 136,418 ) — ( 59,975 ) — Balance - end of period $ 34,615 $— $ 340 $— Series C Warrants Series D Warrants December 31, December 31, December 31, December 31, Balance - beginning of period $— $— $— $— Warrants issued during the period 4,046,836 — 3,080,121 — Warrants exercised during the period ( 365,224 ) — ( 1,403,776 ) — Change in fair value ( 3,339,370 ) — ( 1,337,675 ) — Translation effect ( 121,760 ) — ( 51,319 ) — Balance - end of period $ 220,482 $— $ 287,351 $— Series E Warrants December 31, December 31, Balance - beginning of period $— $— Warrants issued during the period 7,029,614 — Change in fair value ( 6,128,344 ) — Balance - end of period $ 901,270 $— The fair value of the derivative warrant liabilities was estimated using the Black-Scholes option pricing model and based on the following assumptions: 2020 Warrants 2021 Warrants December 31, December 31, December 31, December 31, Share price N/A $ 14.35 N/A $ 14.35 Exercise price N/A $ 78.75 N/A $ 78.75 Dividend yield N/A — N/A — Risk-free interest N/A 1.10 % N/A 1.22 % Remaining contractual life (years) N/A 3.81 N/A 4.64 Expected volatility N/A 80.4 % N/A 79.2 % Series A Warrants Series B Warrants December 31, December 31, December 31, December 31, Share price $ 0.32 $— $ 0.32 $— Exercise price $ 11.20 $— $ 11.20 $— Dividend yield — — — — Risk-free interest 4.02 % — 4.75 % — Remaining contractual life (years) 4.71 — 0.71 — Expected volatility 94.2 % — 135.7 % — Series C Warrants Series D Warrants December 31, June 23, 2022 December 31, June 23, 2022 Share price $ 0.32 $ 2.90 $ 0.32 $ 2.90 Exercise price $ 2.32 $ 2.32 $ 2.32 $ 2.32 Dividend yield — — — — Risk-free interest 4.05 % 3.38 % 4.58 % 3.21 % Remaining contractual life (years) 4.48 5.00 1.48 2.00 Expected volatility 94.1 % 84.0 % 112.4 % 88.7 % Series E Warrants December 31, October 11, 2022 Share price $ 0.32 $ 1.54 Exercise price $ 1.62 $ 1.62 Dividend yield — — Risk-free interest 4.02 % 4.14 % Remaining contractual life (years) 4.78 5.00 Expected volatility 93.6 % 90.4 % The Company measured its derivative warrant liabilities at fair value on a recurring basis. These financial liabilities were measured using level 3 inputs. The Company uses the historical volatility of the underlying share to establish the expected volatility of the warrants. An increase or decrease in this assumption to estimate the fair values using the Black-Scholes option pricing model would result in an increase or a decrease in the fair value of the instruments, respectively.

Loans and Borrowings

Loans and Borrowings	9 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Loans and borrowings	9. Loans and borrowings: December 31, March 31, Loans and borrowings: Promissory note originally of $ 10,000,000 and increased to $ 13,000,000 on July 13, 2022, issued by Sprout, guaranteed by the Company and secured through a first-ranking mortgage on all movable current and future, corporeal and incorporeal, and tangible and intangible assets of Sprout. The outstanding principal balance bears interest at the rate of 10.0 % per annum, increasing by 1.00 % every three months commencing September 30, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs. The principal and accrued interest may also be converted, in whole or in part, at any time before February 1, 2024, upon the mutual consent of Sprout, the Company and MSEC, into common shares of the Company. $ 15,261,355 $ 11,648,320 Promissory note of $ 250,000 issued by Sprout on August 26, 2022, guaranteed by the Company and secured by the issued and outstanding capital stock of Sprout. The outstanding principal balance bears interest at the rate of 10.0 % per annum, increasing by 1.00 % every three months commencing September 30, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs. The principal is payable on February 1, 2024 in cash, or, upon the prior consent of the holder, fully or partially in common shares of Neptune at the Company's discretion. 201,428 — Promissory notes totaling $ 550,000 issued by Sprout on November 8, 2022, guaranteed by the Company and secured by the issued and outstanding capital stock of Sprout. The outstanding principal balance bears interest at the rate of 10.0 % per annum, increasing by 1.00 % every three months commencing December 31, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs. The principal is payable on February 1, 2024 in cash, or, upon the prior consent of the holder, fully or partially in common shares of Neptune at the Company's discretion. 473,875 — 15,936,658 11,648,320 Less current portion of loans and borrowings — — Loans and borrowings $ 15,936,658 $ 11,648,320 On July 13, 2022, Sprout entered into an amendment of each of its existing Secured Promissory Notes. In connection with this amendment, investment funds managed by Morgan Stanley Expansion Capital ("Morgan Stanley" or "MSEC") agreed to immediately commit an additional $ 3 million in Secured Promissory Notes to Sprout. The maturity date of the note facility of February 1, 2024 is consistent with the maturity date of the existing Secured Promissory Notes with MSEC and Neptune. The $ 13.0 million of amended S ecured Promissory Notes have a 10 % interest rate per annum, increasing by 1% per annum every three months during the term of the S ecured Promissory Notes . The interest will be compounded and added to the principal amount on a quarterly basis. MSEC was issued 372,670 common shares of Neptune, of a value of $ 570,185 , in connection with this commitment. On August 26, 2022, Sprout entered into an additional $ 250,000 Secured Promissory Note, which is on the same terms as the Secured Promissory Note entered into with MSEC discussed above. Neptune issued 36,765 common shares for a value of $ 75,736 in connection with this Secured Promissory Note in connection with this commitment. On November 8, 2022, Sprout entered into three agreements to issue an additional aggregate $ 550,000 of Secured Promissory Notes, on the same terms as the Secured Promissory Note entered into with MSEC discussed above. In connection with these financings, Neptune issued 146,330 common shares for a value of $ 96,578 to the holders of these Secured Promissory Notes o n February 15, 2023. During the three and nine-month periods ended December 31, 2022, interest expense of $ 311,679 and $ 786,311 respectively were recognized on loans and borrowings (2021 - $ 252,055 and $ 756,888 ). All covenants for the loans and borrowings outstanding as at December 31, 2022 and March 31, 2022 were respected .

Capital and other components of

Capital and other components of equity	9 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Capital and other components of equity	10. Capital and other components of equity: (a) Share capital: Authorized capital stock: Unlimited number of shares without par value: • Common shares Preferred shares, issuable in series, rights, privileges and restrictions determined at time of issuance: • Series A preferred shares, non-voting, non-participating, fixed, preferential, and non-cumulative dividend of 5 % of paid-up capital, exchangeable at the holder’s option under certain conditions into common shares ( no ne issued and outstanding). All issued shares are fully paid. (b) Share options exercised: During the three and nine-month periods ended December 31, 2022 and 2021, Neptune issued no common shares of the Company upon exercise of stock options. (c) DSUs released: During the three and nine-month periods ended December 31, 2022 and 2021 , Neptune issued no common shares of the Company for the release of DSUs to former and current members of the Board of Directors. (d) RSUs released: During the nine-month period ended December 31, 2022, Neptune issued 269,599 common shares of the Company for RSUs released to the CEO as part of his employment agreement at a weighted average price of $ 5.60 per common share. The Company, with the consent of the CEO delayed issuance of an additional 173,493 RSUs. Withholding taxes of $ 815,953 were paid by the Company pursuant to the issuance of these RSUs. During the nine-month period ended December 31, 2021, Neptune issued 51,095 common shares of the Company to the CEO as part of his employment agreement at a weighted average price of $ 155.05 per common share. Withholding taxes of $ 978,699 were paid by the Company pursuant to the issuance of these RSUs, resulting in the Company not issuing an additional 27,133 RSUs. (e) Restricted shares: During the three and nine-month periods ended December 31, 2022 and 2021 , Neptune issued no restricted common shares of the Company to employees. (f) Warrants: As of October 1, 2022, as a result of the change in functional currency of Neptune, the 2020 Warrants and 2021 Warrants no longer met the criteria for liability classification and therefore were reclassified as equity prospectively. The reclassification did not impact the net earnings for the period. On June 23, 2022, as part of the June 2022 Direct Offering described under not e 8, Neptune issued a total of 645,526 pre-funded warrants (“Pre-Funded Warrants”), with each Pre-Funded Warrant exercisable for one Common Share. The Pre-Funded Warrants were funded in full at closing except for a nominal exercise price of $ 0.001 and were exercisable commencing on the Closing Date, and were to terminate when such Pre-Funded Warrants would be exercised in full. The Pre-funded warrants were fully exercised on June 24, 2022 for $ 65 . Changes in the value of equity related to the warrants were as follows: December 31, 2022 December 31, 2021 Weighted Weighted average Number of average Number of exercise price warrants exercise price warrants Warrants outstanding at April 1, 2022 and 2021 $ 325.34 176,429 $ 325.34 176,429 Issued 0.0001 645,526 — — Reclassification from liability related to warrants 78.75 497,355 — — Exercised 0.0001 ( 645,526 ) — — Warrants outstanding at December 31, 2022 $ 120.36 673,784 $ 325.34 176,429 Warrants exercisable at December 31, 2022 $ 143.32 673,784 $ 325.34 176,429 Warrants of the Company classified as equity are composed of the following as at December 31, 2022 and March 31, 2022: December 31, 2022 March 31, 2022 Number Number Number Number outstanding exercisable Amount outstanding exercisable Amount Warrants IFF (i) 57,143 57,143 1,630,210 57,143 57,143 1,630,210 Warrants AMI (ii) 119,286 119,286 4,449,680 119,286 119,286 4,449,680 2020 Warrants (iii) 300,926 300,926 19,058 — — — 2021 Warrants (iv) 196,429 196,429 18,652 — — — 673,784 673,784 $ 6,117,600 176,429 176,429 $ 6,079,890 (i) During the year ended March 31, 2020, Neptune granted 57,143 warrants (“Warrants IFF”) with an exercise price of $ 420.00 expiring o n November 7, 2024 . The warrants, granted in exchange for services to be rendered by non-employees, vest proportionally to the services rendered. No expense was recognized during the three and nine-month periods ended December 31, 2022 (2021 - $ 25,267 and $ 178,917 respectively) under the research and development expenses. (ii) During the year ended March 31, 2020, Neptune granted 119,286 warrants (“Warrants AMI”) with an exercise price of $ 280.00 with 85,715 expiring on October 3, 2024 and 33,572 expiring on February 5, 2025 . The warrants, granted in exchange for services to be rendered by non-employees, vest proportionally to the services rendered. The warrants fully vested in fiscal year ended March 31, 2021 and as such no expense was recognized in relation to those instruments since then. (iii) During the year ended March 31, 2021, Neptune issued a total of 300,926 warrants (“2020 Warrants”) with an exercise price of $ 78.75 expiring on October 22, 2025 . The warrants, issued as part of the Private Placement entered into on October 20, 2020, are exercisable beginning anytime on or after April 22, 2021 until October 22, 2025. Initially classified as liability, the 2020 Warrants which had a fair value of $ 19,058 were reclassified as equity on October 1, 2022 as a result of the change in functional currency. The holders of these warrants will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares. (iv) On February 19, 2021, the Corporation issued 196,429 warrants (“2021 Warrants”) with an exercise price of $ 78.75 expiring on August 19, 2026 . The warrants, issued as part of a Registered Direct Offering entered into on February 17, 2021, are exercisable beginning anytime on or after August 19, 2021 until August 19, 2026. Initially classified as liability, the 2021 Warrants which had a fair value of $ 18,652 were reclassified as equity on October 1, 2022 as a result of the change in functional currency. The holders of these warrants will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares. (g) Common shares issued in connection with debt financing: On July 13, 2022, Neptune issued 372,670 common shares for a value of $ 570,185 in connection with the amendment of the Secured Promissory Notes that were issued by Sprout for the payment of borrowing costs. In connection with this amendment, investment funds managed by MSEC have provided an additional $ 3 million in Secured Promissory Notes to Sprout. On September 9, 2022, Neptune issued 36,765 common shares for a value of $ 75,736 in connection with a new $ 250,000 Secured Promissory Notes that were issued by Sprout, for the payment of borrowing costs.

Non-controlling Interest

Non-controlling Interest	9 Months Ended
	Dec. 31, 2022
Noncontrolling Interest [Abstract]
Non-controlling Interest	11. Non-controlling interest: The summarized financial information of Sprout is provided below. This information is based on amounts before inter-company eliminations and include the effects of the Company’s purchase price adjustments. Summarized statement of loss and comprehensive loss: Three-month period ended Nine-month period ended December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 Revenue from contracts with customers $ 8,380,966 $ 6,791,703 $ 24,903,038 $ 19,456,048 Cost of sales ( 7,825,211 ) ( 7,020,841 ) ( 23,748,469 ) ( 19,914,902 ) Selling, general and administrative expenses ( 3,184,805 ) ( 2,185,582 ) ( 9,412,606 ) ( 7,157,115 ) Impairment loss on goodwill and intangible assets — — ( 10,164,000 ) — Finance costs ( 934,685 ) ( 1,184,310 ) ( 2,396,967 ) ( 1,857,471 ) Loss before tax ( 3,563,735 ) ( 3,599,030 ) ( 20,819,004 ) ( 9,473,440 ) Income tax (expense) recovery ( 14,543 ) 50 ( 14,543 ) ( 11,894 ) Net loss ( 3,578,278 ) ( 3,598,980 ) ( 20,833,547 ) ( 9,485,334 ) Total comprehensive loss ( 3,578,278 ) ( 3,598,980 ) ( 20,833,547 ) ( 9,485,334 ) Loss attributable to the subsidiary's non-controlling interest ( 1,785,561 ) ( 1,803,089 ) ( 10,395,940 ) ( 4,752,152 ) Comprehensive loss attributable to the subsidiary's non-controlling interest $( 1,785,561 ) $( 1,795,891 ) $( 10,395,940 ) $( 4,733,182 ) Summarized statement of balance sheets: December 31, March 31, Current assets $ 13,911,380 12,260,375 Non-current assets 28,184,381 39,000,367 Current liabilities 8,010,791 5,991,483 Non-current liabilities 34,454,862 25,362,259 Total equity ( 369,892 ) 19,907,000 Attributable to: Equity holders of the Company $( 2,696,029 ) $ 7,184,923 Non-controlling interest 2,326,137 12,722,077 Summarized statement of cash flow: Three-month period ended Nine-month period ended December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 Cash flow used in operating activities $( 1,873,210 ) $( 531,533 ) $( 5,798,310 ) $( 8,605,043 ) Cash flow used in investment activities — ( 55,519 ) — ( 56,765 ) Cash flow from financing activities (1) 1,999,408 859,130 5,249,408 8,831,765 Net increase (decrease) in cash and cash equivalents $ 126,198 $ 272,078 $( 548,902 ) $ 169,957 (1) Cash flow from financing activities is partially provided through intercompany advances.

Share-based Payment

Share-based Payment	9 Months Ended
	Dec. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-based Payment	12. Share-based payment: Under the Company’s share-based payment arrangements, stock-based compensation expenses of $ 1,005,455 and $ 2,832,438 were recognized on equity share based awards and expenses of $ 110,859 and $ 3,263,437 on liability based awards in the consolidated statement of loss and comprehensive loss for the three and nine-month periods ended December 31, 2022 respectively (2021 - equity expenses of $ 1,013,795 and $ 6,251,713 respectively) and nil for liability based awards for the three and nine-month periods ended December 31, 2021. As at December 31, 2022, the Company had the following share-based payment arrangements: (a) Company stock option plan: (i) Stock option plan: The Company has established a stock option plan for directors, officers, employees and consultants. The exercise price of the stock options granted under the plan is not lower than the closing price of the common shares listed on the Nasdaq on the eve of the grant. The terms and conditions for acquiring and exercising options are set by the Board of Directors, subject to, among others, the following limitations: the term of the options cannot exceed ten years and every stock option granted under the stock option plan will be subject to conditions no less restrictive than a minimum vesting period of 18 months and a gradual and equal acquisition of vesting rights at least on a quarterly basis. The Company’s stock-option plan allows the Company to issue a number of stock options not exceeding 15 % of the number of common shares issued and outstanding at the time of any grant. The total number of stock options issuable to a single holder cannot exceed 5 % of the Company’s total issued and outstanding common shares at the time of the grant, provided that the maximum number of stock options issuable to a single consultant cannot exceed 2 % of the Company's total issued and outstanding common shares at the time of the grant. The number and weighted average exercise prices of stock options are as follows: 2022 2021 Weighted Weighted average average exercise Number of exercise Number of Notes price options price options Options outstanding at April 1st, 2022 and 2021 $ 37.41 306,321 $ 65.91 121,208 Granted 1.60 229,715 29.97 220,125 Forfeited/Cancelled 16.00 ( 65,361 ) 37.82 ( 86,815 ) Expired 50.71 ( 47,033 ) 90.20 ( 7,143 ) Options outstanding at December 31, 2022 and 2021 $ 18.55 423,642 $ 45.10 247,375 Options exercisable at December 31, 2022 and 2021 $ 39.25 131,119 $ 56.59 98,387 December 31, 2022 Options outstanding Exercisable options Weighted remaining Weighted Weighted contractual Number of number of average Exercise life options options exercise price outstanding outstanding exercisable price $ 1.55 - $ 1.59 4.63 115,715 19,048 1.55 $ 1.60 - $ 6.07 4.74 114,000 — — $ 6.08 - $ 27.90 3.71 106,431 57,621 25.51 $ 27.91 - $ 42.96 3.55 28,669 10,804 30.23 $ 42.97 - $ 157.38 7.21 58,827 43,646 76.08 423,642 131,119 The fair value of options granted has been estimated using the Black-Scholes option pricing model and based on the weighted average of certain assumptions. The Company granted respectively no options and 114,000 options to non-employees during the three and nine-month periods ended December 31, 2022 ( none for the three and nine-month periods ended December 31, 2021) resulting in a $ 128,680 and a nil stock-based compensation expense, respectively for the nine-month periods ended December 31, 2022 and 2021. Nine-month periods ended Black Sholes assumptions used December 31, December 31, Share price $ 10.50 -$ 155.05 $ 18.20 -$ 155.05 Exercise price $ 10.50 -$ 155.05 $ 19.25 -$ 155.05 Dividend yield nil nil Risk-free interest 0.13 % - 2.04 % 0.13 % - 2.04 % Expected life (years) 3.54 3.47 Expected volatility 53.52 % - 91.94 % 53.52 % - 86.04 % Stock-based compensation recognized under this plan amounted to $ 299,406 and $ 774,679 respectively for the three and nine-month periods ended December 31, 2022 (2021 - $ 162,735 and $ 1,598,378 ). Unrecognized compensation cost at December 31, 2022 is $ 399,386 with a weighted average period remaining of 1.03 years ( 2021 - $ 1,584,133 with a weighted average period remaining of 1.29 years). (ii) Non-market performance options: On July 8, 2019, the Company granted 100,000 non-market performance options under the Company stock option plan at an exercise price of $ 4.43 per share to the CEO, expiring on July 8, 2029 . These options vest after the attainment of non-market performance conditions within the following ten years . These non-market performance options required the approval of amendments to the stock option plan and therefore the fair value of these options was revalued up to the date of the approval of the amendments (grant date). None of these non-market performance options have vested as at December 31, 2022 . These options were no t exercisable as at December 31, 2022 and 2021. No stock-based compensation expense was recognized during the three and nine-month periods ended December 31, 2022 (three and nine-month periods ended December 31, 2021- $ 99,849 and $ 301,013 respectively). (iii) Market performance options: On July 8, 2019, the Company granted 157,142 market performance options under the Company stock option plan at an exercise price of $ 4.43 per share to the CEO, expiring on July 8, 2029 . These options vest after the attainment of market performance conditions within the following ten years . Some of these market performance options required the approval of amendments to the stock option plan and therefore the fair value of these options was revaluated up to the date of the approval of the amendments (grant date). The number and weighted average exercise prices of market performance options are as follows: 2022 2021 Weighted Weighted average average exercise Number of exercise Number of Notes price options price options Options outstanding at April 1, 2022 and 2021 $ 155.05 157,142 $ 155.05 157,142 Options outstanding at December 31, 2022 and 2021 $ 155.05 157,142 $ 155.05 157,142 Options exercisable at December 31, 2022 and 2021 $ 155.05 21,429 $ 155.05 21,429 Stock-based compensation recognized under this plan amounted to $ 573,588 and $ 1,776,579 respectively for the three and nine-month periods ended December 31, 2022. Stock-based compensation expenses of $ 618,162 and $ 1,863,558 were recognized for three and nine-month periods ended December 31, 2021 respectively. Unrecognized compensation cost at December 31, 2022 is $ 9,484,197 with a weighted average period remaining of 6.76 years (2021 - $ 12,610,370 with a weighted average period remaining of 7.76 years). (b) Deferred Share Units and Restricted Share Units: The Company has established an equity incentive plan for employees, directors and consultants of the Company. The plan provides for the issuance of restricted share units, performance share units, restricted shares, deferred share units and other share-based awards, subject to restricted conditions as may be determined by the Board of Directors. Upon fulfillment of the restricted conditions, as the case may be, the plan provides for settlement of the awards outstanding through shares. (i) Deferred Share Units ("DSUs") The number and weighted average share prices of DSUs are as follows: 2022 2021 Weighted Weighted average average share Number of share Number of Notes price DSUs price DSUs DSUs outstanding at April 1, 2022 and 2021 $ 66.45 4,308 $ 63.00 1,202 DSUs outstanding at December 31, 2022 and 2021 $ 66.45 4,308 $ 19.00 4,308 DSUs exercisable at December 31, 2022 and 2021 $ 66.45 4,308 $ 48.18 1,976 Of the 4,308 DSUs outstanding as at December 31, 2022 (2021 – 4,308 ), 1,555 DSUs vested during the nine-month period ended December 31, 2021 upon services to be rendered during a period of twelve months from date of grant (2021 – 1,108 ). The fair value of the DSUs is determined to be the share price at the date of grant and is recognized as stock-based compensation, through additional paid-in capital, over the vesting period. Stock-based compensation recognized under this plan amounted to $ — and $ 13,025 respectively for the three and nine-month periods ended December 31, 2022. Stock-based compensation expenses of $ 23,928 and $ 29,235 were recognized for three and nine-month periods ended December 31, 2021 respectively. (ii) Restricted Share Units (‘’RSUs’’) During the year ended March 31, 2020, as part of the employment agreement of the CEO, the Company granted RSUs which vest over three years in 36 equal instalments. During the year ended March 31, 2021, Neptune granted additional RSUs to the CEO and to executives of the Company, which vest over periods ranging from 6 months to 3 years. The fair value of the RSUs is determined to be the share price at the date of grant and is recognized as stock-based compensation, through additional paid-in capital, over the vesting period. The fair value of the RSUs granted during the nine-month period ended December 31, 2022 was $ 3.31 per unit. 2022 2021 Weighted Weighted average average share Number of share Number of Notes price RSUs price RSUs RSUs outstanding at April 1st, 2022 and 2021 $ 59.75 25,038 $ 92.08 95,845 Granted 3.31 436,449 — 11,751 Forfeited 19.25 ( 15,606 ) — ( 2,858 ) Released through the issuance of common shares 10(d) 5.60 ( 269,599 ) 155.05 ( 51,095 ) Withheld as payment of withholding taxes 10(d) 5.60 ( 173,493 ) 155.05 ( 27,133 ) RSUs outstanding at December 31, 2022 and 2021 $ 60.04 2,789 $ 148.49 26,510 Stock-based compensation recognized under this plan amounted to $ 132,461 and $ 268,155 respectively for the three and nine-month periods ended December 31, 2022. Stock-based compensation expenses of $ 109,121 and $ 2,459,529 were recognized for three and nine-month periods ended December 31, 2021 respectively. There is no unrecognized compensation cost at December 31, 2022 (2021 - $ 501,720 unrecognized compensation cost with a weighted average remaining life of 0.76 years). On November 14, 2021, the Company and its CEO entered into an agreement pursuant to which the CEO’s existing employment agreement was amended to waive the Company’s obligation to procure directors and officers insurance coverage of up to $ 15 million for the period covering July 1, 2021 to July 31, 2022. The parties agreed that if the Company had successfully completed a strategic partnership prior to December 31, 2021, the CEO would have been entitled to approximately $ 6.9 million in cash and would have been granted fully vested options to purchase 8.5 million shares of the Company’s common stock. As the strategic partnership was not consummated by December 31, 2021, the CEO was entitled to monthly cash payments for an aggregate value of approximately $ 6.9 million or the issuance over time of a fixed amount of fully vested RSUs, at the option of the Company. The balance of the liability accrual to the CEO is $ 8,587 (including withholding taxes) as at December 31, 2022, in trade and other payables. The revaluation of the liability amounted to a loss of $ 110,859 and a gain of $ 3,263,437 respectively for the three and nine-month periods ended December 31, 2022 and were recorded into selling, general and administrative expenses (2021 – nil for both periods). During the three and nine-month periods ended December 31, 2022, settlements in RSUs were of $ 132,681 and $ 1,555,585 respectively. The compensation to be settled in RSUs or if the Company is unable to grant such RSUs, then a combination of cash and vested RSUs with equivalent value, is not reflected in the number of RSUs outstanding above. (c) Long term cash bonus: According to the employment agreement with the CEO, a long-term incentive of $ 15 million is payable if the Company’s US market capitalization is at least $ 1 billion . The Company uses a risk-neutral Monte Carlo simulation to estimate the fair-value of this instrument and recognizes the incentive over the estimated period to reach the market capitalization. As at December 31, 2022, the liability related to this long-term incentive of $ 23,000 ($ 88,688 as at March 31, 2022) is presented in Other liability in the consolidated balance sheets. During the nine-month period ended December 31, 2022, a recovery of $ 65,688 (2021 - a recovery of $ 238,155 ) was recorded in connection with the long-term incentive under selling, general and administrative expenses in the consolidated statement of loss. During the three-month period ended December 31, 2022, the Company recorded a recovery of $ 1,000 (2021 - a recovery of $ 85,468 ).

Income (Loss) per Share

Income (Loss) per Share	9 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Income (Loss) per Share	13. Income ( Loss) per share: The Company presents basic net income per share using the two-class method. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to equity holders and that determines basic net income per share for each class of stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings that would have been available to equity holders. A participating security is defined as a security that may participate in undistributed earnings with shares. The Company’s capital structure includes securities that participate with shares on a one-for-one basis for distribution of dividends. The following classes of warrants are considered participating securities as they are entitled to participate in dividend distributions alongside equity holders for which the two-class method is applied in computing earnings per share: Series A Warrants, Series B Warrants, Series C Warrants, Series D Warrants, Series E Warrants, 2020 Warrants and 2021 Warrants. The Company determines the diluted net income per share by using the more dilutive of the two class-method or the treasury stock method. The issued and unexercised liability and equity classified warrants do not participate in losses of the Company, thus an allocation of losses is not performed when the Company is in a loss position. The effects of options, DSUs, RSUs and warrants are excluded from the calculation of diluted loss per share for periods in which a company sustains a loss. Accordingly, diluted loss per share was the same as basic loss per share, except for the three-month period ended December 31, 2022, because the Company has incurred losses in each of the other periods presented. All outstanding options, DSUs, RSUs and warrants could potentially be dilutive in the future. Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, Net income (loss) attributed to equity holders $ 1,288,110 $( 15,009,015 ) $( 33,893,698 ) $( 43,029,506 ) Less: Undistributed earnings attributed to warrant holders ( 631,070 ) — — — Basic net income (loss) attributed to common shareholders $ 657,040 $( 15,009,015 ) $( 33,893,698 ) $( 43,029,506 ) Dilutive net income (loss) attributed to common shareholders $ 657,040 $( 15,009,015 ) $( 33,893,698 ) $( 43,029,506 ) Basic weighted-average number of common shares outstanding 11,030,838 4,781,190 8,462,761 4,765,762 Effect of dilutive securities Options, RSU's, DSU's 64,129 — — — Dilutive weighted-average number of common shares outstanding 11,094,967 4,781,190 8,462,761 4,765,762 Net income (loss) per share attributable to common shareholders of the Company Basic earnings (loss) per share $ 0.06 $( 3.14 ) $( 4.01 ) $( 9.03 ) Dilutive earnings (loss) per share $ 0.06 $( 3.14 ) $( 4.01 ) $( 9.03 ) The following table summarizes outstanding securities not included in the computation of diluted net income (loss) per share as the effect would have been anti-dilutive for each respective period. Three-month periods ended Nine-month periods ended Securities December 31, December 31, December 31, December 31, Options, RSU's, DSU's 523,752 435,335 587,881 435,335 Warrants 11,236,554 673,784 11,236,554 673,784

Fair Value

Fair Value	9 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value	14. Fair-value: The Company uses various methods to estimate the fair value recognized in the consolidated financial statements. The fair value hierarchy reflects the significance of inputs used in determining the fair values: • Level 1 ‒ Unadjusted quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date; • Level 2 ‒ Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); • Level 3 ‒ Fair value based on valuation techniques which includes inputs related to the asset or liability that are not based on observable market data (unobservable inputs). Financial assets and liabilities measured at fair value on a recurring basis are the assets held for sale, the call option granted to Neptune by Sprout’s non-controlling interest owners of equity (the “Call Option”) and the liability related to warrants. The following table presents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 and March 31, 2022: December 31, 2022 Notes Level 1 Level 2 Level 3 Total Liabilities Liability related to warrants 8 $— $— $ 1,444,058 $ 1,444,058 Total $— $— $ 1,444,058 $ 1,444,058 March 31, 2022 Notes Level 1 Level 2 Level 3 Total Liabilities Liability related to warrants 8 $— $— $ 5,570,530 $ 5,570,530 Total $— $— $ 5,570,530 $ 5,570,530 On June 8, 2022, the Company announced a planned divestiture of the Canadian cannabis business and the Company will focus on winding up its cannabis operations pending one or more sales transactions. Following this announcement, the disposal group was first measured based on level 3 inputs, at fair value less cost to sell using market prices for comparative assets, and then based on level 1 inputs during the quarter ended September 30, 2022, as per the ASPA (note 2(d)). On February 10, 2021, Sprout’s other equity interest owners granted Neptune a call option (the "Call Option") to purchase the remaining 49.9 % outstanding equity interests of Sprout, at any time beginning on January 1, 2023 and ending on December 31, 2023. On December 31, 2022 and March 31, 2022 , the Call Option was measured based on level 3 inputs to nil . For the three and nine-month periods ended December 31, 2022 , the Company recorded gains on re-measurement of nil ( 2021 - losses of $ ( 376,753 ) and $ ( 146,138 ) respectively). The liabilities related to warrants were recorded at their fair value using a Black-Scholes pricing model. Warrants are revalued each period end at fair value through profit and loss using level 3 inputs (note 8). The Company has determined that the carrying values of its short-term financial assets and liabilities approximate their fair values given the short-term nature of these instruments. The carrying value of the short-term investment also approximates its fair value given the short-term maturity of the reinvested funds. For variable rate loans and borrowings, the fair value is considered to approximate the carrying amount. The fair value of the fixed rate loans and borrowings and long-term payable is determined by discounting future cash flows using a rate that the Company could obtain for loans with similar terms, conditions and maturity dates. The fair value of these instruments approximates the carrying amounts and was measured using level 3 inputs.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	. Commitments and contingencies: (a) Commitments: (i) On January 31, 2020, Neptune entered into an exclusive license agreement for a specialty ingredient in combination with fish oil products in nutraceutical products for a period of 8 years . Neptune is required to pay royalties on sales for these products. To maintain exclusivity, Neptune must reach annual minimum volumes of sales for the duration of the agreement or make corresponding minimum royalty payments. The total remaining amount of minimum royalties under the license agreement is $ 1,148,564 . Failure to make the minimum royalty payments will solely result in the license granted thereunder becoming non-exclusive. (ii) On March 21, 2019, the Company received a judgment from the Court regarding certain previously disclosed claims made by a corporation controlled by the former CEO against the Company in respect to certain royalty payments alleged to be owed and owing to the former CEO pursuant to the terms of an agreement entered into on February 23, 2001 between Neptune and the former CEO (the “Agreement”). The Court declared that under the terms of the agreement, the Company is required to pay royalties of 1 % of its revenues in semi-annual instalments, for an unlimited period. Based on currently available information, a provision of $ 606,346 for royalty payments has been recognized as of December 31, 2022 ( $ 362,809 as at March 31, 2022). Refer to note 7. (iii) On May 28, 2021, Sprout entered into a license agreement with Moonbug Entertainment Limited (“Moonbug”), pursuant to which it would license certain intellectual property, relating to characters from the children’s entertainment property CoComelon, for use on certain Sprout products through December 31, 2023 in exchange for a royalty on net sales. Sprout is required to make minimum guaranteed annual payments to Moonbug of $ 200,000 over the term of the agreement. The agreement may be extended for an additional three years in exchange for an additional minimum guaranteed annual payment to Moonbug of $ 200,000 over the extended term of the agreement. Royalties payable under the agreement are set off against minimum guaranteed payments made. (b) Contingencies: In the normal course of business, the Company is involved in various claims and legal proceedings, for which the outcomes, inflow or outflow of economic benefits, are uncertain. The most significant of which are ongoing are as follows: (i) In September 2020, Neptune submitted a claim and demand for arbitration against Peter M. Galloway and PMGSL Holdings, LLC (collectively “PMGSL”) in accordance with the SugarLeaf Asset Purchase Agreement (“APA”) dated May 9, 2019 between Neptune, PMGSL, Peter M. Galloway and Neptune Holding USA, Inc. Separately, PMGSL submitted a claim and demand for arbitration against Neptune. The Neptune claims and PMGSL claims have been consolidated into a single arbitration and each are related to the purchase by Neptune of substantially all of the assets of the predecessor entities of PMGSL Holdings, LLC. Neptune is claiming, among other things, breach of contract and negligent misrepresentation by PMGSL in connection with the APA and is seeking, among other things, equitable restitution and any and all damages recoverable under law. PMGSL is claiming, among other things, breach of contract by Neptune and is seeking, among other things, payment of certain compensation contemplated by the APA. A merit hearing in the arbitration started in April 2022 with a further week of testimony from August 1-5, 2022. On June 15, 2022, a one-day hearing took place on Neptune's motion to enforce a settlement agreement reached on April 2021 (which was repudiated by PMGSL in June 2021). Following oral argument on July 7, 2022, that motion was denied. While Neptune believes there is no merit to the claims brought by PMGSL, a judgment in favor of PMGSL may have a material adverse effect on our business and Neptune intends to continue vigorously defending itself. Based on currently available information, a provision of $ 600,000 has been recognized for this case as at December 31, 2022 ($ 600,000 as at March 31, 2022). (ii) On February 4, 2021, the United States House of Representatives Subcommittee on Economic and Consumer Policy, Committee on Oversight and Reform (the “Subcommittee”), published a report, “Baby Foods Are Tainted with Dangerous Levels of Arsenic, Lead, Cadmium, and Mercury” (the “Report”), which stated that, with respect to Sprout, “independent testing of Sprout Organic Foods” has confirmed that their baby foods contain concerning levels of toxic heavy metals.” The Report further stated that after receiving reports alleging high levels of toxic metals in baby foods, the Subcommittee requested information from Sprout but did not receive a response. On February 11, 2021, following the acquisition of a 50.1 % stake in Sprout by Neptune, the Subcommittee contacted Sprout, reiterating its requests for documents and information about toxic heavy metals in Sprout’s baby foods. Sprout provided an initial response to the Subcommittee on February 25, 2021 and is cooperating with the Subcommittee requests . Further, on February 24, 2021, the Office of the Attorney General of the State of New Mexico (“NMAG”) delivered to Sprout a civil investigative demand requesting similar documents and information with regards to the Report and the NMAG’s investigation into possible violations of the False Advertising Act of New Mexico. Sprout is responding to the requests of the NMAG. Since February 2021, several putative consumer class action lawsuits have been brought against Sprout alleging that its products (the “Products”) contain unsafe and undisclosed levels of various naturally occurring heavy metals, namely lead, arsenic, cadmium and mercury. Sprout has denied the allegations in these lawsuits and contends that its baby foods are safe and properly labeled. The claims raised in these lawsuits were brought in the wake of the highly publicized Report. All such putative class actions have since been dismissed. No provision has been recorded in the financial statements for these cases. In addition to the consumer class actions discussed above, Sprout is currently named in three lawsuits (filed in California State Court on June 16, 2021, filed in Hawaii State Court on January 9, 2023 and filed in Nevada Federal Court on March 3, 2023, respectively) alleging some form of personal injury from the ingestion of Sprout’s Products, purportedly due to unsafe and undisclosed levels of various naturally occurring heavy metals. These lawsuits generally allege injuries related to neurological development disorders such as autism spectrum disorder and attention deficit hyperactivity disorder. Sprout denies that its Products contributed to any of these injuries. In addition, the Office of the Attorney General for the District of Columbia (“OAG”) sent a letter to Sprout dated October 1, 2021, similar to letters sent to other baby food manufacturers, alleging potential labeling and marketing misrepresentations and omissions regarding the health and safety of its baby food products, constituting an unlawful trade practice. Sprout has agreed to meet with the OAG and will vigorously defend against the allegations. No provision has been recorded in the financial statements for this matter. These matters may have a material adverse effect on Sprout's financial condition, or results of operations. The outcome of these claims and legal proceedings against the Company cannot be determined with certainty and is subject to future resolution, including the uncertainties of litigation.

Operating Segments

Operating Segments	9 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Operating Segments	16. Operating Segments: The Company measures its performance based on a single segment, which is the consolidated level used in internal management reports that are reviewed by the Company’s Chief Operating Decision Maker. a) Geographical information: Revenue is attributed to geographical locations based on the origin of customers’ location: Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, Canada $ 1,347,700 $ 4,560,116 $ 7,074,759 $ 8,920,392 United States 10,597,392 9,831,143 32,626,483 27,643,347 Other countries 263,816 276,670 766,736 701,330 $ 12,208,908 $ 14,667,929 $ 40,467,978 $ 37,265,069 Long-lived assets of the Company are located in the following geographical location: December 31, March 31, Canada $ 536,905 $ 20,724,674 United States 1,325,762 723,449 Total property, plant and equipment $ 1,862,667 $ 21,448,123 December 31, March 31, Canada $ 1,688,339 $ 2,353,054 United States 15,654,839 19,301,981 Total intangible assets $ 17,343,178 $ 21,655,035 December 31, March 31, Canada $ 2,424,414 $ 2,625,851 United States 11,971,966 19,542,437 Total goodwill $ 14,396,380 $ 22,168,288 b) Revenues The Company derives revenue from the sales of goods which are recognized at a point in time as follows: Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, Nutraceutical products $ 3,541,002 $ 3,927,334 $ 11,844,529 $ 11,168,555 Cannabis and hemp products 23,337 3,516,488 2,740,664 5,659,039 Food and beverages products 8,380,753 6,927,617 25,083,053 19,606,381 Innovation products — ( 344 ) — 68,515 $ 11,945,092 $ 14,371,095 $ 39,668,246 $ 36,502,490

Related Parties

Related Parties	9 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related parties	17. Related parties: Related party transactions and balances not disclosed elsewhere in these notes of the financial statements are as follows: On November 11, 2019, Neptune announced that the Company entered into a collaboration agreement with International Flavors & Fragrances Inc. (“IFF”) to co-develop hemp-derived products for the mass retail and health and wellness markets. App Connect Service, Inc. (“App Connect”), a company indirectly controlled by Michael Cammarata, CEO and Director of Neptune, is also a party to the agreement to provide related branding strategies and promotional activities. Neptune will be responsible for the marketing and the sales of the products and will receive the amounts from the product sales. Neptune will in turn pay a royalty to IFF and App Connect associated with the sales of the co-developed products. The payment of royalties to App Connect, subject to certain conditions, has been approved by the TSX. During the three and nine-month periods ended December 31, 2022 and 2021, the Company recorded a negligible amount of royalty expense pursuant to the co-development contract and no royalties were paid to date.

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent event	18. Subsequent events: On January 13, 2023, Neptune announced that it has closed on a senior secured notes financing (such notes, the "Notes") for gross proceeds of $ 4,000,000 with CCUR Holdings, Inc. and Symbolic Logic, Inc. (collectively, the "Noteholders"). The Notes will mature 12 months from the initial closing and bear interest at a rate of 16.5 % per annum. The notes are secured by the assets of Neptune excluding the assets of Sprout. Interest will be payable in kind on the first 6 monthly payment dates after the initial closing date and thereafter will be payable in cash. Pursuant to the terms of the Notes, the Company also issued to the Noteholders warrants to purchase an aggregate of 850,000 shares of Neptune common stock, with each warrant exercisable for 5 years following the initial issuance at a price of $ 0.53 per common share. On March 9, 2023, the Company entered into a Waiver and First Amendment to the Notes (the "Waiver Agreement"). The Waiver Agreement waives certain administrative, regulatory and financial statement related covenants as further described in the Waiver Agreement as required by the terms of the Notes. The lender has the right to demand immediate repayment in the event of default. Furthermore, in connection with the Waiver Agreement, the Notes were amended to provide that the Purchasers shall be paid an exit fee in the aggregate amount of $ 200,000 , payable as follows: (i) on or prior to May 15, 2023, $ 100,000 and (ii) on the Maturity Date (as defined in the Note Purchase Agreement), $ 100,000 and the interest rate was increased to 24 % for a period extending until the Company meets specified criteria in the Waiver Agreement. On January 25, 2023, Neptune announced that its organic baby food brand subsidiary, Sprout Organics, has entered into an accounts receivable factoring facility with Alterna Capital Solutions, LLC ("Alterna"). The maximum available is $ 5 million. The terms of the agreement include a Funds Usage Fee of prime plus 1 % with a minimum interest rate of 8 % per annum. Alterna was granted a security interest in Sprout's accounts receivable. The agreement will remain in effect for a 12-month period, effective January 23, 2023, and will be automatically renewed. Neptune provided a commercial guaranty in connection with this agreement.

Significant accounting polici_2

Significant accounting policies (Policies)	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of consolidation	(a) Basis of consolidation: These consolidated financial statements include the accounts of the Company and its subsidiaries in which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated from the Company’s consolidated financial statements. On February 10, 2021, Neptune acquired a 50.1 % interest in Sprout Foods, Inc. (“Sprout” or “Sprout Foods”). The accounts of the subsidiary are included in the consolidated financial statements from that date.
New standards and interpretations not yet adopted	(b) New standards and interpretations not yet adopted: Accounting pronouncements not yet adopted In October 2021, the FASB issued ASU 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which amends ASC Topic 805, Business Combinations, ASU 2021-18 improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to the (1) recognition of an acquired contract liability and (2) payment terms and their direct effect on subsequent revenue recognized by the acquirer. ASU 2021-08 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2022. Management has not yet evaluated the impact of this ASU on the Company's consolidated financial statements and the Company does not intend to adopt ASU 2021-18 until its fiscal year beginning April 1, 2023. In June 2016, the FASB issued ASU 2016-13, Financial instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the guidance on the impairment of financial instruments by requiring measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, and earlier adoption is permitted beginning in the first quarter of fiscal 2019. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will still have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. The Company will adopt ASU 2016-13 for its fiscal year beginning April 1, 2023, and the Company’s evaluation of the potential impact of adoption is in process.
Assets held for sale	(c) Assets held for sale: The Company classifies long-lived assets or disposal groups to be sold as assets held for sale in the period in which all of the following conditions are met: management, having the authority to approve the action, commits to a plan to sell the asset or disposal group; the asset or disposal group is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets or disposal groups; an active program to locate a buyer and other actions required to complete the plan to sell the asset or disposal group have been initiated; the sale of the asset or disposal group is probable, and transfer of the asset or disposal group is expected to qualify for recognition of a completed sale within one year; the assets of disposal group are subject to an asset sale and purchase agreement (see notes 2(d)); and actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Assets and liabilities directly associated with assets held for sale are measured at the lower of carrying amount and fair value less costs to sell immediately prior to their classification. Any loss resulting from this measurement is recognized in the period in which the held-for sale criteria are met. Conversely, gains are not recognized on the sale of a long-lived asset or disposal group until the date of the sale. Assets classified as held for sale, and the assets and liabilities included within the disposal group classified as held for sale are presented separately on the face of the balance sheet. Non-current assets that are classified as held for sale are not depreciated.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	December 31, March 31, Raw materials $ 5,154,170 $ 7,920,190 Work in progress — 1,016,916 Finished goods 11,433,593 7,974,690 Supplies and spare parts 355,045 147,610 $ 16,942,808 $ 17,059,406

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Aggregate Amount of Goodwill is Allocated to Each Reporting Unit	The aggregate amount of goodwill is allocated to each reporting unit as follows: December 31, March 31, Biodroga $ 2,424,414 $ 2,625,851 Sprout 11,971,966 19,542,437 $ 14,396,380 $ 22,168,288

Liability Related to Warrants (

Liability Related to Warrants (Tables)	9 Months Ended
	Dec. 31, 2022
Warrants And Rights Note Disclosure [Abstract]
Summary of Changes in Value of Liability Related to Warrants	Changes in the value of the liability related to the warrants for the nine-month period ended December 31, 2022 and 2021 were as follows: Warrants Amount Outstanding as at March 31, 2021 497,355 $ 10,462,137 Revaluation ( 8,853,111 ) Movements in exchange rates 32,916 Outstanding as at December 31, 2021 497,355 1,641,942 Outstanding as at March 31, 2022 1,925,929 $ 5,570,530 Warrants issued during the period 10,308,166 14,156,571 Warrants exercised during the period ( 1,173,970 ) ( 1,769,000 ) Warrants reclassified to equity during the period ( 497,355 ) ( 37,710 ) Revaluation gain ( 16,083,681 ) Movements in exchange rates ( 392,652 ) Outstanding as at December 31, 2022 10,562,770 1,444,058
Summary of Outstanding Warrants	The following table provides the relevant information on the outstanding warrants as at December 31, 2022: Reference Date of issuance Number of warrants outstanding Number of warrants exercisable Exercise price Expiry date Series A Warrants March 14, 2022 714,287 714,287 $ 11.20 September 14, 2027 Series B Warrants March 14, 2022 714,287 714,287 $ 11.20 March 14, 2028 Series C Warrants June 23, 2022 771,556 771,556 $ 2.32 June 23, 2027 Series C Warrants June 23, 2022 972,763 972,763 $ 2.32 June 23, 2029 Series D Warrants June 23, 2022 972,763 972,763 $ 2.32 June 24, 2024 Series E Warrants October 11, 2022 6,417,114 6,417,114 $ 1.62 October 11, 2027 10,562,770 10,562,770 $ 3.10
Summary of Reconciliation of Changes in Fair Value of Warrants	The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value for the respective nine-month periods is presented in the following tables: 2020 Warrants 2021 Warrants December 31, December 31, December 31, December 31, Balance - beginning of period $ 309,769 $ 6,174,137 $ 306,704 $ 4,288,000 Warrants reclassified to equity during the period ( 19,058 ) — ( 18,652 ) — Change in fair value to date of transfer to equity ( 279,056 ) ( 5,300,014 ) ( 276,527 ) ( 3,553,097 ) Translation effect ( 11,655 ) 20,701 ( 11,525 ) 12,215 Balance - end of period $— $ 894,824 $— $ 747,118 Series A Warrants Series B Warrants December 31, December 31, December 31, December 31, Balance - beginning of period $ 3,270,816 $— $ 1,683,241 $— Change in fair value ( 3,099,783 ) — ( 1,622,926 ) — Translation effect ( 136,418 ) — ( 59,975 ) — Balance - end of period $ 34,615 $— $ 340 $— Series C Warrants Series D Warrants December 31, December 31, December 31, December 31, Balance - beginning of period $— $— $— $— Warrants issued during the period 4,046,836 — 3,080,121 — Warrants exercised during the period ( 365,224 ) — ( 1,403,776 ) — Change in fair value ( 3,339,370 ) — ( 1,337,675 ) — Translation effect ( 121,760 ) — ( 51,319 ) — Balance - end of period $ 220,482 $— $ 287,351 $— Series E Warrants December 31, December 31, Balance - beginning of period $— $— Warrants issued during the period 7,029,614 — Change in fair value ( 6,128,344 ) — Balance - end of period $ 901,270 $—
Summary of Fair Value of Derivative Warrant Liabilities Estimated Using Black-Scholes Option Pricing Model	The fair value of the derivative warrant liabilities was estimated using the Black-Scholes option pricing model and based on the following assumptions: 2020 Warrants 2021 Warrants December 31, December 31, December 31, December 31, Share price N/A $ 14.35 N/A $ 14.35 Exercise price N/A $ 78.75 N/A $ 78.75 Dividend yield N/A — N/A — Risk-free interest N/A 1.10 % N/A 1.22 % Remaining contractual life (years) N/A 3.81 N/A 4.64 Expected volatility N/A 80.4 % N/A 79.2 % Series A Warrants Series B Warrants December 31, December 31, December 31, December 31, Share price $ 0.32 $— $ 0.32 $— Exercise price $ 11.20 $— $ 11.20 $— Dividend yield — — — — Risk-free interest 4.02 % — 4.75 % — Remaining contractual life (years) 4.71 — 0.71 — Expected volatility 94.2 % — 135.7 % — Series C Warrants Series D Warrants December 31, June 23, 2022 December 31, June 23, 2022 Share price $ 0.32 $ 2.90 $ 0.32 $ 2.90 Exercise price $ 2.32 $ 2.32 $ 2.32 $ 2.32 Dividend yield — — — — Risk-free interest 4.05 % 3.38 % 4.58 % 3.21 % Remaining contractual life (years) 4.48 5.00 1.48 2.00 Expected volatility 94.1 % 84.0 % 112.4 % 88.7 % Series E Warrants December 31, October 11, 2022 Share price $ 0.32 $ 1.54 Exercise price $ 1.62 $ 1.62 Dividend yield — — Risk-free interest 4.02 % 4.14 % Remaining contractual life (years) 4.78 5.00 Expected volatility 93.6 % 90.4 %

Loans and Borrowings (Tables)

Loans and Borrowings (Tables)	9 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Summary of Loans and Borrowings	December 31, March 31, Loans and borrowings: Promissory note originally of $ 10,000,000 and increased to $ 13,000,000 on July 13, 2022, issued by Sprout, guaranteed by the Company and secured through a first-ranking mortgage on all movable current and future, corporeal and incorporeal, and tangible and intangible assets of Sprout. The outstanding principal balance bears interest at the rate of 10.0 % per annum, increasing by 1.00 % every three months commencing September 30, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs. The principal and accrued interest may also be converted, in whole or in part, at any time before February 1, 2024, upon the mutual consent of Sprout, the Company and MSEC, into common shares of the Company. $ 15,261,355 $ 11,648,320 Promissory note of $ 250,000 issued by Sprout on August 26, 2022, guaranteed by the Company and secured by the issued and outstanding capital stock of Sprout. The outstanding principal balance bears interest at the rate of 10.0 % per annum, increasing by 1.00 % every three months commencing September 30, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs. The principal is payable on February 1, 2024 in cash, or, upon the prior consent of the holder, fully or partially in common shares of Neptune at the Company's discretion. 201,428 — Promissory notes totaling $ 550,000 issued by Sprout on November 8, 2022, guaranteed by the Company and secured by the issued and outstanding capital stock of Sprout. The outstanding principal balance bears interest at the rate of 10.0 % per annum, increasing by 1.00 % every three months commencing December 31, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs. The principal is payable on February 1, 2024 in cash, or, upon the prior consent of the holder, fully or partially in common shares of Neptune at the Company's discretion. 473,875 — 15,936,658 11,648,320 Less current portion of loans and borrowings — — Loans and borrowings $ 15,936,658 $ 11,648,320

Capital and other components _2

Capital and other components of equity (Tables)	9 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Summary of Warrants	Changes in the value of equity related to the warrants were as follows: December 31, 2022 December 31, 2021 Weighted Weighted average Number of average Number of exercise price warrants exercise price warrants Warrants outstanding at April 1, 2022 and 2021 $ 325.34 176,429 $ 325.34 176,429 Issued 0.0001 645,526 — — Reclassification from liability related to warrants 78.75 497,355 — — Exercised 0.0001 ( 645,526 ) — — Warrants outstanding at December 31, 2022 $ 120.36 673,784 $ 325.34 176,429 Warrants exercisable at December 31, 2022 $ 143.32 673,784 $ 325.34 176,429 Warrants of the Company classified as equity are composed of the following as at December 31, 2022 and March 31, 2022: December 31, 2022 March 31, 2022 Number Number Number Number outstanding exercisable Amount outstanding exercisable Amount Warrants IFF (i) 57,143 57,143 1,630,210 57,143 57,143 1,630,210 Warrants AMI (ii) 119,286 119,286 4,449,680 119,286 119,286 4,449,680 2020 Warrants (iii) 300,926 300,926 19,058 — — — 2021 Warrants (iv) 196,429 196,429 18,652 — — — 673,784 673,784 $ 6,117,600 176,429 176,429 $ 6,079,890 (i) During the year ended March 31, 2020, Neptune granted 57,143 warrants (“Warrants IFF”) with an exercise price of $ 420.00 expiring o n November 7, 2024 . The warrants, granted in exchange for services to be rendered by non-employees, vest proportionally to the services rendered. No expense was recognized during the three and nine-month periods ended December 31, 2022 (2021 - $ 25,267 and $ 178,917 respectively) under the research and development expenses. (ii) During the year ended March 31, 2020, Neptune granted 119,286 warrants (“Warrants AMI”) with an exercise price of $ 280.00 with 85,715 expiring on October 3, 2024 and 33,572 expiring on February 5, 2025 . The warrants, granted in exchange for services to be rendered by non-employees, vest proportionally to the services rendered. The warrants fully vested in fiscal year ended March 31, 2021 and as such no expense was recognized in relation to those instruments since then. (iii) During the year ended March 31, 2021, Neptune issued a total of 300,926 warrants (“2020 Warrants”) with an exercise price of $ 78.75 expiring on October 22, 2025 . The warrants, issued as part of the Private Placement entered into on October 20, 2020, are exercisable beginning anytime on or after April 22, 2021 until October 22, 2025. Initially classified as liability, the 2020 Warrants which had a fair value of $ 19,058 were reclassified as equity on October 1, 2022 as a result of the change in functional currency. The holders of these warrants will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares. (iv) On February 19, 2021, the Corporation issued 196,429 warrants (“2021 Warrants”) with an exercise price of $ 78.75 expiring on August 19, 2026 . The warrants, issued as part of a Registered Direct Offering entered into on February 17, 2021, are exercisable beginning anytime on or after August 19, 2021 until August 19, 2026. Initially classified as liability, the 2021 Warrants which had a fair value of $ 18,652 were reclassified as equity on October 1, 2022 as a result of the change in functional currency. The holders of these warrants will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares. (g) Common shares issued in connection with debt financing: On July 13, 2022, Neptune issued 372,670 common shares for a value of $ 570,185 in connection with the amendment of the Secured Promissory Notes that were issued by Sprout for the payment of borrowing costs. In connection with this amendment, investment funds managed by MSEC have provided an additional $ 3 million in Secured Promissory Notes to Sprout. On September 9, 2022, Neptune issued 36,765 common shares for a value of $ 75,736 in connection with a new $ 250,000 Secured Promissory Notes that were issued by Sprout, for the payment of borrowing costs.

Non-controlling Interest (Table

Non-controlling Interest (Tables)	9 Months Ended
	Dec. 31, 2022
Noncontrolling Interest [Abstract]
Summarized Financial Information of Non-controlling Interest	Summarized statement of loss and comprehensive loss: Three-month period ended Nine-month period ended December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 Revenue from contracts with customers $ 8,380,966 $ 6,791,703 $ 24,903,038 $ 19,456,048 Cost of sales ( 7,825,211 ) ( 7,020,841 ) ( 23,748,469 ) ( 19,914,902 ) Selling, general and administrative expenses ( 3,184,805 ) ( 2,185,582 ) ( 9,412,606 ) ( 7,157,115 ) Impairment loss on goodwill and intangible assets — — ( 10,164,000 ) — Finance costs ( 934,685 ) ( 1,184,310 ) ( 2,396,967 ) ( 1,857,471 ) Loss before tax ( 3,563,735 ) ( 3,599,030 ) ( 20,819,004 ) ( 9,473,440 ) Income tax (expense) recovery ( 14,543 ) 50 ( 14,543 ) ( 11,894 ) Net loss ( 3,578,278 ) ( 3,598,980 ) ( 20,833,547 ) ( 9,485,334 ) Total comprehensive loss ( 3,578,278 ) ( 3,598,980 ) ( 20,833,547 ) ( 9,485,334 ) Loss attributable to the subsidiary's non-controlling interest ( 1,785,561 ) ( 1,803,089 ) ( 10,395,940 ) ( 4,752,152 ) Comprehensive loss attributable to the subsidiary's non-controlling interest $( 1,785,561 ) $( 1,795,891 ) $( 10,395,940 ) $( 4,733,182 ) Summarized statement of balance sheets: December 31, March 31, Current assets $ 13,911,380 12,260,375 Non-current assets 28,184,381 39,000,367 Current liabilities 8,010,791 5,991,483 Non-current liabilities 34,454,862 25,362,259 Total equity ( 369,892 ) 19,907,000 Attributable to: Equity holders of the Company $( 2,696,029 ) $ 7,184,923 Non-controlling interest 2,326,137 12,722,077 Summarized statement of cash flow: Three-month period ended Nine-month period ended December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 Cash flow used in operating activities $( 1,873,210 ) $( 531,533 ) $( 5,798,310 ) $( 8,605,043 ) Cash flow used in investment activities — ( 55,519 ) — ( 56,765 ) Cash flow from financing activities (1) 1,999,408 859,130 5,249,408 8,831,765 Net increase (decrease) in cash and cash equivalents $ 126,198 $ 272,078 $( 548,902 ) $ 169,957 (1) Cash flow from financing activities is partially provided through intercompany advances.

Share-based Payment (Tables)

Share-based Payment (Tables)	9 Months Ended
	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Number and Weighted Average Exercise Prices of Market Performance Options	December 31, 2022 Options outstanding Exercisable options Weighted remaining Weighted Weighted contractual Number of number of average Exercise life options options exercise price outstanding outstanding exercisable price $ 1.55 - $ 1.59 4.63 115,715 19,048 1.55 $ 1.60 - $ 6.07 4.74 114,000 — — $ 6.08 - $ 27.90 3.71 106,431 57,621 25.51 $ 27.91 - $ 42.96 3.55 28,669 10,804 30.23 $ 42.97 - $ 157.38 7.21 58,827 43,646 76.08 423,642 131,119
Summary of Number and Weighted Average Share Prices of DSUs	The number and weighted average share prices of DSUs are as follows: 2022 2021 Weighted Weighted average average share Number of share Number of Notes price DSUs price DSUs DSUs outstanding at April 1, 2022 and 2021 $ 66.45 4,308 $ 63.00 1,202 DSUs outstanding at December 31, 2022 and 2021 $ 66.45 4,308 $ 19.00 4,308 DSUs exercisable at December 31, 2022 and 2021 $ 66.45 4,308 $ 48.18 1,976
Summary of Number and Weighted Average Share Prices of RSUs	2022 2021 Weighted Weighted average average share Number of share Number of Notes price RSUs price RSUs RSUs outstanding at April 1st, 2022 and 2021 $ 59.75 25,038 $ 92.08 95,845 Granted 3.31 436,449 — 11,751 Forfeited 19.25 ( 15,606 ) — ( 2,858 ) Released through the issuance of common shares 10(d) 5.60 ( 269,599 ) 155.05 ( 51,095 ) Withheld as payment of withholding taxes 10(d) 5.60 ( 173,493 ) 155.05 ( 27,133 ) RSUs outstanding at December 31, 2022 and 2021 $ 60.04 2,789 $ 148.49 26,510
Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Stock Option Plan	The number and weighted average exercise prices of stock options are as follows: 2022 2021 Weighted Weighted average average exercise Number of exercise Number of Notes price options price options Options outstanding at April 1st, 2022 and 2021 $ 37.41 306,321 $ 65.91 121,208 Granted 1.60 229,715 29.97 220,125 Forfeited/Cancelled 16.00 ( 65,361 ) 37.82 ( 86,815 ) Expired 50.71 ( 47,033 ) 90.20 ( 7,143 ) Options outstanding at December 31, 2022 and 2021 $ 18.55 423,642 $ 45.10 247,375 Options exercisable at December 31, 2022 and 2021 $ 39.25 131,119 $ 56.59 98,387
Summary of Assumptions Used to Determine Fair Value of Options Granted	Nine-month periods ended Black Sholes assumptions used December 31, December 31, Share price $ 10.50 -$ 155.05 $ 18.20 -$ 155.05 Exercise price $ 10.50 -$ 155.05 $ 19.25 -$ 155.05 Dividend yield nil nil Risk-free interest 0.13 % - 2.04 % 0.13 % - 2.04 % Expected life (years) 3.54 3.47 Expected volatility 53.52 % - 91.94 % 53.52 % - 86.04 %
Market Performance Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Stock Option Plan	The number and weighted average exercise prices of market performance options are as follows: 2022 2021 Weighted Weighted average average exercise Number of exercise Number of Notes price options price options Options outstanding at April 1, 2022 and 2021 $ 155.05 157,142 $ 155.05 157,142 Options outstanding at December 31, 2022 and 2021 $ 155.05 157,142 $ 155.05 157,142 Options exercisable at December 31, 2022 and 2021 $ 155.05 21,429 $ 155.05 21,429

Income (Loss) per Share (Tables

Income (Loss) per Share (Tables)	9 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Summary of Earnings Per Share Basic and Diluted	Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, Net income (loss) attributed to equity holders $ 1,288,110 $( 15,009,015 ) $( 33,893,698 ) $( 43,029,506 ) Less: Undistributed earnings attributed to warrant holders ( 631,070 ) — — — Basic net income (loss) attributed to common shareholders $ 657,040 $( 15,009,015 ) $( 33,893,698 ) $( 43,029,506 ) Dilutive net income (loss) attributed to common shareholders $ 657,040 $( 15,009,015 ) $( 33,893,698 ) $( 43,029,506 ) Basic weighted-average number of common shares outstanding 11,030,838 4,781,190 8,462,761 4,765,762 Effect of dilutive securities Options, RSU's, DSU's 64,129 — — — Dilutive weighted-average number of common shares outstanding 11,094,967 4,781,190 8,462,761 4,765,762 Net income (loss) per share attributable to common shareholders of the Company Basic earnings (loss) per share $ 0.06 $( 3.14 ) $( 4.01 ) $( 9.03 ) Dilutive earnings (loss) per share $ 0.06 $( 3.14 ) $( 4.01 ) $( 9.03 )
Summary of Outstanding Securities not Included in Computation of Diluted Net Income (Loss) Per Share	The following table summarizes outstanding securities not included in the computation of diluted net income (loss) per share as the effect would have been anti-dilutive for each respective period. Three-month periods ended Nine-month periods ended Securities December 31, December 31, December 31, December 31, Options, RSU's, DSU's 523,752 435,335 587,881 435,335 Warrants 11,236,554 673,784 11,236,554 673,784

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table presents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 and March 31, 2022: December 31, 2022 Notes Level 1 Level 2 Level 3 Total Liabilities Liability related to warrants 8 $— $— $ 1,444,058 $ 1,444,058 Total $— $— $ 1,444,058 $ 1,444,058 March 31, 2022 Notes Level 1 Level 2 Level 3 Total Liabilities Liability related to warrants 8 $— $— $ 5,570,530 $ 5,570,530 Total $— $— $ 5,570,530 $ 5,570,530

Operating Segments (Tables)

Operating Segments (Tables)	9 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Summary of Revenue Attributed to Geographical Locations	Revenue is attributed to geographical locations based on the origin of customers’ location: Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, Canada $ 1,347,700 $ 4,560,116 $ 7,074,759 $ 8,920,392 United States 10,597,392 9,831,143 32,626,483 27,643,347 Other countries 263,816 276,670 766,736 701,330 $ 12,208,908 $ 14,667,929 $ 40,467,978 $ 37,265,069
Summary of Long-Lived Assets by Geographical Location	Long-lived assets of the Company are located in the following geographical location: December 31, March 31, Canada $ 536,905 $ 20,724,674 United States 1,325,762 723,449 Total property, plant and equipment $ 1,862,667 $ 21,448,123 December 31, March 31, Canada $ 1,688,339 $ 2,353,054 United States 15,654,839 19,301,981 Total intangible assets $ 17,343,178 $ 21,655,035 December 31, March 31, Canada $ 2,424,414 $ 2,625,851 United States 11,971,966 19,542,437 Total goodwill $ 14,396,380 $ 22,168,288
Summary of Revenue Derived from Sale of Goods	The Company derives revenue from the sales of goods which are recognized at a point in time as follows: Three-month periods ended Nine-month periods ended December 31, December 31, December 31, December 31, Nutraceutical products $ 3,541,002 $ 3,927,334 $ 11,844,529 $ 11,168,555 Cannabis and hemp products 23,337 3,516,488 2,740,664 5,659,039 Food and beverages products 8,380,753 6,927,617 25,083,053 19,606,381 Innovation products — ( 344 ) — 68,515 $ 11,945,092 $ 14,371,095 $ 39,668,246 $ 36,502,490

Reporting Entity - Additional I

Reporting Entity - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022	Jun. 13, 2022	Jun. 09, 2022	Feb. 10, 2021
Reporting Entity [Line Items]
Common shares issued	11,778,392		11,778,392		5,560,829
Common stock outstanding	11,778,392		11,778,392		5,560,829
Net loss	$ 497,451	$ 16,804,906	$ 44,289,638	$ 47,762,688	$ 84,400,000
Cash flow from operations			20,669,892	43,820,603	54,300,000
Accumulated deficit	357,075,395		357,075,395		$ 323,181,697
Cash on hand	$ 3,404,023	$ 13,158,605	$ 3,404,023	$ 13,158,605
Pre-Consolidation Shares
Reporting Entity [Line Items]
Common shares issued							198,000,000
Common stock outstanding							198,000,000
Post-Consolidation Shares
Reporting Entity [Line Items]
Common shares issued						5,700,000
Common stock outstanding						5,700,000
Sprout
Reporting Entity [Line Items]
Acquired interest	50.10%		50.10%					50.10%

Basis of Preparation - Addition

Basis of Preparation - Additional Information (Details)			3 Months Ended	9 Months Ended
	Oct. 16, 2022 USD ($)	Oct. 16, 2022 CAD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of asset sale and purchase agreement	$ 3,790,340	$ 5,150,000
Assets held for sale	3,203,557
Impairment loss			$ 0	$ (15,346,119)
Canadian Cannabis
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Expected cost to sell Canadian cannabis disposal group asset	$ 586,783

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Details)	Dec. 31, 2022	Feb. 10, 2021
Sprout
Significant Accounting Policies [Line Items]
Acquired interest	50.10%	50.10%

Business Combination - Addition

Business Combination - Additional Information (Details)	Feb. 10, 2021
Sprout
Business Acquisition [Line Items]
Minority ownership percentage	49.90%

Business Combination - Summary

Business Combination - Summary of Final Purchase Price Allocation of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 14,396,380	$ 22,168,288

Business Combination - Summar_2

Business Combination - Summary of Final Purchase Price Allocation of Assets Acquired and Liabilities Assumed (Parenthetical) (Details)	Feb. 10, 2021
Sprout
Business Acquisition [Line Items]
Non-controlling interest percentage	49.90%

Trade and Other Receivables - S

Trade and Other Receivables - Summary of Trade and Other Receivables (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Receivables [Abstract]
Trade and other receivables	$ 4,919,568	$ 7,599,584

Inventories - Summary of Invent

Inventories - Summary of Inventories (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 5,154,170	$ 7,920,190
Work in progress		1,016,916
Finished goods	11,433,593	7,974,690
Supplies and spare parts	355,045	147,610
Inventory	$ 16,942,808	$ 17,059,406

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Impairment losses of inventories	$ 0	$ 2,996,333	$ 3,079,997	$ 2,996,333

Property, Plant and Equipment -

Property, Plant and Equipment - Additional Information (Details) - USD ($)	3 Months Ended			9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Impairment loss		$ 0		$ (15,346,119)
Canadian Cannabis
Property Plant And Equipment [Line Items]
Impairment charge					$ 1,424,517
Cannabis
Property Plant And Equipment [Line Items]
Property, plant and equipment impaired	$ 0		$ 0	$ 15,346,119	2,404,459
Impairment loss			$ 10,243
SugarLeaf
Property Plant And Equipment [Line Items]
Impairment charge					$ 979,942

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Lessee Lease Description [Line Items]
Operating lease costs	$ 385,800	$ 563,428
Right-of-use asset	$ 2,144,362		$ 2,295,263

Leases - Summary of Lease Liabi

Leases - Summary of Lease Liabilities Amounts Recognized in Consolidated Balance Sheets (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Leases [Abstract]
Current	$ 489,849	$ 641,698
Non-current	$ 2,229,583	$ 2,063,421

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2022
Goodwill [Line Items]
Impairment loss on goodwill			$ 7,570,471
Post tax discount rate	11%
Business plan duration	3 years
Operating result growth rate	3.50%
Sprout
Goodwill [Line Items]
Impairment loss on goodwill	$ 7,570,471
Impairment charge	$ 0	$ 2,593,529

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Aggregate Amount of Goodwill is Allocated to Each Reporting Unit (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Goodwill [Line Items]
Goodwill	$ 14,396,380	$ 22,168,288
Biodroga
Goodwill [Line Items]
Goodwill	2,424,414	2,625,851
Sprout
Goodwill [Line Items]
Goodwill	$ 11,971,966	$ 19,542,437

Trade and Other Payables - Summ

Trade and Other Payables - Summary of Trade and Other Payables (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Payables [Abstract]
Trade and other payables current	$ 21,984,254	$ 22,700,849

Provisions - Additional Informa

Provisions - Additional Information (Details)			3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 22, 2023 USD ($)	Oct. 21, 2022 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) Instalment	Dec. 31, 2021 USD ($)	Mar. 31, 2019	Mar. 31, 2022 USD ($)	Mar. 23, 2022 USD ($)
Related Party Transaction [Line Items]
Annual royalties percentage of sales and other revenue									1%
Litigation related to provision for royalty payments			$ 606,346				$ 606,346			$ 362,809
Litigation related to provision for royalty payments increased amount			64,415			$ 135,757	281,244	$ 651,229
Litigation related to provision for currency translation adjustments			9,317			(6,061)	(37,707)	3,750
Payments related to litigation provision						$ 7,515	$ 0	$ 1,763,991
Arbitrator's award with fees and cost including applicable interest											$ 1,127,024
Settlement agreement date					July 13, 2022
Settlement amount					$ 543,774
Settlement gain under selling, general and administrative expenses					$ 583,430
Litigation settlement description							The settlement was subject to court approval and certification by the court of the class. On March 16, 2023 the settlement offer was accepted and the first payment in the amount of $500,000 was paid on March 22, 2023. Two additional payments of $500,000 each are due 30 days and 60 days after the first payment. The rest is payable either in cash ($2,500,000) or in shares ($2,750,000) at Neptune's election, within 31 days after the Final Approval Order is entered.
Number of instalments for litigation settlement expense payable | Instalment							2
Litigation settlement expense payable in installment			500,000				$ 500,000
Litigation settlement expense payable in cash			2,500,000				2,500,000
Litigation settlement expense payable in shares			2,750,000				2,750,000
Other provisions for legal fees obligations			730,587				730,587			155,804
Litigation settlement balance payable amount			0				0
Subsequent Event
Related Party Transaction [Line Items]
Litigation settlement amount	$ 500,000
PMGSL
Related Party Transaction [Line Items]
Provision for litigation			600,000				600,000			600,000
Supplier
Related Party Transaction [Line Items]
Litigation related to provision for currency translation adjustments				$ (12,496)
Payments related to litigation provision				$ 187,025
Corporation and Certain of Current and Former Officers
Related Party Transaction [Line Items]
Litigation related to provision and expense within selling general administration for royalty payments			$ 4,000,000				$ 4,000,000			$ 0
Corporation and Certain of Current and Former Officers | Maximum
Related Party Transaction [Line Items]
Litigation settlement amount		$ 4,250,000
Corporation and Certain of Current and Former Officers | Minimum
Related Party Transaction [Line Items]
Litigation settlement amount		$ 4,000,000

Liability Related to Warrants -

Liability Related to Warrants - Additional Information (Details) - USD ($)					1 Months Ended	9 Months Ended
	Oct. 11, 2022	Oct. 06, 2022	Jun. 24, 2022	Jun. 23, 2022	Aug. 31, 2022	Dec. 31, 2022
Class Of Warrant Or Right [Line Items]
Number of warrants issued						10,308,166
Shares issued during period, shares	3,208,557
Class of warrant or right, number of securities called by warrants or rights					972,763
Combined purchase price for one common share and one warrant	$ 1.87
Net proceeds from share issuance	$ 6,000,002
Proceeds to liabilities, initial liability	7,029,614
Net proceeds from issuance of common stock	5,135,002
Loss on warrants	$ 1,029,614
Proceeds from the issuance of shares and warrants through a Direct Offering				$ 5,000,002
Exercise price of warrants	$ 1.62				$ 2.32	$ 3.10
Residual amount allocated						$ (2,126,955)
Exercise price	$ 1.62				$ 2.32	$ 3.10
Warrants exercised (shares)					384,446
Warrants exercised					$ 1,769,000	$ 1,769,000
Private Placement
Class Of Warrant Or Right [Line Items]
Total issue costs						$ 465,211
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants issued	6,417,114
Common Shares
Class Of Warrant Or Right [Line Items]
Shares issued during period, shares				1,300,000
Number of shares exercisable for common share				1
Total issue costs	$ 865,000
Prefunded Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants issued				645,526
Exercise price of warrants				$ 0.0001
Proceeds from exercise of warrants			$ 65
Exercise price				$ 0.0001
Series C Warrants
Class Of Warrant Or Right [Line Items]
Class of warrant or right, number of securities called by warrants or rights				1,945,526	201,207
Exercise price of warrants						$ 2.32
Warrant exercisable term						5 years
Exercise price						$ 2.32
Change in fair value of warrant liability						$ (3,339,370)
Class of warrants or rights for which termination date has been extended		972,763
Extended termination date		2 years
Series C Warrants | Black-Scholes Model
Class Of Warrant Or Right [Line Items]
Initial warrant liability						$ 4,046,836
Series D warrants
Class Of Warrant Or Right [Line Items]
Class of warrant or right, number of securities called by warrants or rights				1,945,526
Exercise price of warrants						$ 2.32
Warrant exercisable term						2 years
Combined offering price of warrants				$ 2.57
Exercise price						$ 2.32
Change in fair value of warrant liability						$ (1,337,675)
Series D warrants | Black-Scholes Model
Class Of Warrant Or Right [Line Items]
Initial warrant liability						$ 3,080,121

Liability Related to Warrants_2

Liability Related to Warrants - Summary of Changes in Value of Liability Related to Warrants (Details) - USD ($)	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Warrants And Rights Note Disclosure [Abstract]
Number of warrants outstanding, beginning balance	1,925,929	497,355
Warrants issued during the period	10,308,166
Warrants exercised during the period	(1,173,970)
Warrants reclassified to equity during the period	(497,355)
Number of warrants outstanding, ending balance	10,562,770	497,355
Warrants outstanding, beginning balance	$ 5,570,530	$ 10,462,137
Warrants issued during the period	14,156,571
Warrants exercised during the period	(1,769,000)
Warrants reclassified to equity during the period	(37,710)
Revaluation gain	(16,083,681)	(8,853,111)
Movements in exchange rates	(392,652)	32,916
Warrants outstanding, ending balance	$ 1,444,058	$ 1,641,942

Liability Related to Warrants_3

Liability Related to Warrants - Summary of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Dec. 31, 2022	Oct. 11, 2022	Aug. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	10,562,770			1,925,929	497,355	497,355
Number of warrants exercisable	10,562,770
Exercise price	$ 3.10	$ 1.62	$ 2.32
Series A Warrants
Class Of Warrant Or Right [Line Items]
Date of issuance	Mar. 14, 2022
Number of warrants outstanding	714,287
Number of warrants exercisable	714,287
Exercise price	$ 11.20
Expiry date	Sep. 14, 2027
Series B Warrants
Class Of Warrant Or Right [Line Items]
Date of issuance	Mar. 14, 2022
Number of warrants outstanding	714,287
Number of warrants exercisable	714,287
Exercise price	$ 11.20
Expiry date	Mar. 14, 2028
Series C Warrants
Class Of Warrant Or Right [Line Items]
Date of issuance	Jun. 23, 2022
Number of warrants outstanding	771,556
Number of warrants exercisable	771,556
Exercise price	$ 2.32
Expiry date	Jun. 23, 2027
Series C Warrants
Class Of Warrant Or Right [Line Items]
Date of issuance	Jun. 23, 2022
Number of warrants outstanding	972,763
Number of warrants exercisable	972,763
Exercise price	$ 2.32
Expiry date	Jun. 23, 2029
Series D warrants
Class Of Warrant Or Right [Line Items]
Date of issuance	Jun. 23, 2022
Number of warrants outstanding	972,763
Number of warrants exercisable	972,763
Exercise price	$ 2.32
Expiry date	Jun. 24, 2024
Series E Warrants
Class Of Warrant Or Right [Line Items]
Date of issuance	Oct. 11, 2022
Number of warrants outstanding	6,417,114
Number of warrants exercisable	6,417,114
Exercise price	$ 1.62
Expiry date	Oct. 11, 2027

Liability Related to Warrants_4

Liability Related to Warrants - Summary of Reconciliation of Changes in Fair Value of Warrants (Details) - USD ($)	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Warrants outstanding, beginning balance	$ 5,570,530	$ 10,462,137
Warrants issued during the period	14,156,571
Warrants exercised during the period	(1,769,000)
Warrants reclassified to equity during the period	37,710
Warrants outstanding, ending balance	1,444,058	1,641,942
2020 Warrants
Class Of Warrant Or Right [Line Items]
Warrants outstanding, beginning balance	309,769	6,174,137
Warrants reclassified to equity during the period	(19,058)
Change in fair value to date of transfer to equity	(279,056)	(5,300,014)
Translation effect	(11,655)	20,701
Warrants outstanding, ending balance		894,824
2021 Warrants
Class Of Warrant Or Right [Line Items]
Warrants outstanding, beginning balance	306,704	4,288,000
Warrants reclassified to equity during the period	(18,652)
Change in fair value to date of transfer to equity	(276,527)	(3,553,097)
Translation effect	(11,525)	12,215
Warrants outstanding, ending balance		$ 747,118
Series A Warrants
Class Of Warrant Or Right [Line Items]
Warrants outstanding, beginning balance	3,270,816
Change in fair value	(3,099,783)
Translation effect	(136,418)
Warrants outstanding, ending balance	34,615
Series B Warrants
Class Of Warrant Or Right [Line Items]
Warrants outstanding, beginning balance	1,683,241
Change in fair value	(1,622,926)
Translation effect	(59,975)
Warrants outstanding, ending balance	340
Series C Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued during the period	4,046,836
Warrants exercised during the period	(365,224)
Change in fair value	(3,339,370)
Translation effect	(121,760)
Warrants outstanding, ending balance	220,482
Series D warrants
Class Of Warrant Or Right [Line Items]
Warrants issued during the period	3,080,121
Warrants exercised during the period	(1,403,776)
Change in fair value	(1,337,675)
Translation effect	(51,319)
Warrants outstanding, ending balance	287,351
Series E Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued during the period	7,029,614
Change in fair value	(6,128,344)
Warrants outstanding, ending balance	$ 901,270

Liability Related to Warrants_5

Liability Related to Warrants - Summary of Fair Value of Derivative Warrant Liabilities Estimated Using Black-Scholes Option Pricing Model (Details) - Black-Scholes Option Pricing Model	Dec. 31, 2022 yr $ / shares	Oct. 11, 2022	Jun. 23, 2022	Dec. 31, 2021 yr $ / shares
2020 Warrants | Share Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input				14.35
2020 Warrants | Exercise Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input				78.75
2020 Warrants | Risk Free Interest
Class Of Warrant Or Right [Line Items]
Warrants, measurement input				1.10
2020 Warrants | Remaining Contractual Life (Years)
Class Of Warrant Or Right [Line Items]
Warrants, measurement input | yr				3.81
2020 Warrants | Expected Volatility
Class Of Warrant Or Right [Line Items]
Warrants, measurement input				80.4
2021 Warrants | Share Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input				14.35
2021 Warrants | Exercise Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input				78.75
2021 Warrants | Risk Free Interest
Class Of Warrant Or Right [Line Items]
Warrants, measurement input				1.22
2021 Warrants | Remaining Contractual Life (Years)
Class Of Warrant Or Right [Line Items]
Warrants, measurement input | yr				4.64
2021 Warrants | Expected Volatility
Class Of Warrant Or Right [Line Items]
Warrants, measurement input				79.2
Series A Warrants | Share Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input | yr	0.32
Series A Warrants | Exercise Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	11.20
Series A Warrants | Risk Free Interest
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	4.02
Series A Warrants | Remaining Contractual Life (Years)
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	4.71
Series A Warrants | Expected Volatility
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	94.2
Series B Warrants | Share Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input | yr	0.32
Series B Warrants | Exercise Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	11.20
Series B Warrants | Risk Free Interest
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	4.75
Series B Warrants | Remaining Contractual Life (Years)
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	0.71
Series B Warrants | Expected Volatility
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	135.7
Series C Warrants | Share Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	0.32		2.90
Series C Warrants | Exercise Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	2.32		2.32
Series C Warrants | Risk Free Interest
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	4.05		3.38
Series C Warrants | Remaining Contractual Life (Years)
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	4.48		5
Series C Warrants | Expected Volatility
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	94.1		84
Series D warrants | Share Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	0.32		2.90
Series D warrants | Exercise Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	2.32		2.32
Series D warrants | Risk Free Interest
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	4.58		3.21
Series D warrants | Remaining Contractual Life (Years)
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	1.48		2
Series D warrants | Expected Volatility
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	112.4		88.7
Series E Warrants | Share Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	0.32	1.54
Series E Warrants | Exercise Price
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	1.62	1.62
Series E Warrants | Risk Free Interest
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	4.02	4.14
Series E Warrants | Remaining Contractual Life (Years)
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	4.78	5
Series E Warrants | Expected Volatility
Class Of Warrant Or Right [Line Items]
Warrants, measurement input	93.6	90.4

Loans and Borrowings - Summary

Loans and Borrowings - Summary of Loans and Borrowings (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Loans and borrowings:
Total loans and borrowings	$ 15,936,658	$ 11,648,320
Loans and borrowings	15,936,658	11,648,320
Promissory Note
Loans and borrowings:
Total loans and borrowings	15,261,355	$ 11,648,320
Commercial Paper Two
Loans and borrowings:
Total loans and borrowings	201,428
Commercial Paper Three
Loans and borrowings:
Total loans and borrowings	$ 473,875

Loans and Borrowings - Summar_2

Loans and Borrowings - Summary of Loans and Borrowings (Parenthetical) (Details)	9 Months Ended
	Dec. 31, 2022 USD ($)
Promissory Note
Debt Instrument [Line Items]
Loans and borrowings, interest rate	10%
Loans and borrowings, interest rate during every three months	1%
Loans and borrowings, interest payable description	The outstanding principal balance bears interest at the rate of 10.0% per annum, increasing by 1.00% every three months commencing September 30, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs.
Promissory Note | Minimum
Debt Instrument [Line Items]
Loans and borrowings	$ 10,000,000
Promissory Note | Maximum
Debt Instrument [Line Items]
Loans and borrowings	13,000,000
Commercial Paper Two
Debt Instrument [Line Items]
Loans and borrowings	$ 250,000
Loans and borrowings, interest rate	10%
Loans and borrowings, interest rate during every three months	1%
Loans and borrowings, interest payable description	The outstanding principal balance bears interest at the rate of 10.0% per annum, increasing by 1.00% every three months commencing September 30, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs.
Loans and borrowings, payable date	Feb. 01, 2024
Commercial Paper Three
Debt Instrument [Line Items]
Loans and borrowings	$ 550,000
Loans and borrowings, interest rate	10%
Loans and borrowings, interest rate during every three months	1%
Loans and borrowings, payable date	Feb. 01, 2024

Loans and Borrowings - Summar_3

Loans and Borrowings - Summary of Loans and Borrowings - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Nov. 08, 2022	Sep. 09, 2022	Aug. 26, 2022	Jul. 13, 2022	Mar. 31, 2022
Debt Instrument [Line Items]
Interest expense	$ 311,679	$ 252,055	$ 786,311	$ 756,888
Number of shares issued	11,778,392		11,778,392						5,560,829
Common shares issued, value	$ 321,791,727		$ 321,791,727						$ 317,051,125
Neptune
Debt Instrument [Line Items]
Number of shares issued					146,330		36,765
Common shares issued, value					$ 96,578		$ 75,736
Amended Promissory Notes
Debt Instrument [Line Items]
Secured Promissory Notes								$ 13,000,000
Secured Promissory Notes, Interest rate								10%
Secured Promissory Notes, interest payable description			The $13.0 million of amended Secured Promissory Notes have a 10% interest rate per annum, increasing by 1% per annum every three months during the term of the Secured Promissory Notes. The interest will be compounded and added to the principal amount on a quarterly basis.
Promissory Note
Debt Instrument [Line Items]
Secured Promissory Notes, Interest rate	10%		10%
Secured Promissory Notes, interest payable description			The outstanding principal balance bears interest at the rate of 10.0% per annum, increasing by 1.00% every three months commencing September 30, 2022. Interest is accrued and added to the principal amount of the loan and is presented net of borrowing costs.
Secured Promissory Note Agreement | Sprout
Debt Instrument [Line Items]
Additional amount committed					$ 550,000		$ 250,000
Sprout
Debt Instrument [Line Items]
Number of shares issued						36,765		372,670
Common shares issued, value						$ 75,736		$ 570,185
Sprout | Amended Promissory Notes
Debt Instrument [Line Items]
Additional amount committed						$ 250,000		$ 3,000,000
Sprout | Promissory Note
Debt Instrument [Line Items]
Maturity date of note			Feb. 01, 2024

Capital and Other Components _3

Capital and Other Components of Equity - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended
	Oct. 11, 2022	Jun. 23, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Sep. 09, 2022	Aug. 31, 2022	Jul. 13, 2022	Mar. 31, 2022
Class Of Stock [Line Items]
Percentage of dividend issued on paid up capital					5%
Number of shares issued			11,778,392		11,778,392					5,560,829
Exercise price of warrants	$ 1.62		$ 3.10		$ 3.10			$ 2.32
Number of warrants issued					10,308,166
Proceeds from exercise of warrants		$ 5,000,002
Common shares issued, value			$ 321,791,727		$ 321,791,727					$ 317,051,125
Sprout
Class Of Stock [Line Items]
Number of shares issued							36,765		372,670
Common shares issued, value							$ 75,736		$ 570,185
Sprout | Amended Promissory Notes
Class Of Stock [Line Items]
Additional amount committed							$ 250,000		$ 3,000,000
Direct Offering
Class Of Stock [Line Items]
Prefund warrant description		Pre-Funded Warrant exercisable for one Common Share.
Exercise price of warrants		$ 0.001
Proceeds from exercise of warrants					5,000,002
Registered Direct Offering Priced At-the-market and Concurrent Private Placement
Class Of Stock [Line Items]
Proceeds from exercise of warrants					$ 6,000,002
Maximum
Class Of Stock [Line Items]
Number of warrants issued	6,417,114
DSUs | Board of Directors
Class Of Stock [Line Items]
Number of shares issued			0	0	0	0
RSUs | CEO
Class Of Stock [Line Items]
Number of shares issued			269,599	51,095	269,599	51,095
Share issued price per share			$ 5.60	$ 155.05	$ 5.60	$ 155.05
Withholding taxes paid to issuance of RSUs					$ 815,953	$ 978,699
Withheld as payment of withholding taxes			173,493	27,133	173,493	27,133
Restricted Common Shares | Employees
Class Of Stock [Line Items]
Number of shares issued			0	0	0	0
Prefunded Warrants
Class Of Stock [Line Items]
Number of warrants issued		645,526
Prefunded Warrants | Direct Offering
Class Of Stock [Line Items]
Proceeds from exercise of warrants		$ 65
Series A Preferred Shares
Class Of Stock [Line Items]
Number of shares issued			0		0
Number of shares outstanding			0		0
Stock Options Exercised
Class Of Stock [Line Items]
Share options exercised, shares			0	0	0	0

Capital and Other Components _4

Capital and Other Components of Equity - Summary of Changes in Value of Equity (Details) - $ / shares		9 Months Ended
	Oct. 11, 2022	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Class Of Warrant Or Right [Line Items]
Warrants outstanding, Weighted average exercise price	$ 1.62	$ 3.10
Number of warrants outstanding, beginning balance		1,925,929	497,355
Number of warrants issued		10,308,166
Number of warrants exercised		1,173,970
Number of warrants outstanding, ending balance		10,562,770	497,355
Warrants
Class Of Warrant Or Right [Line Items]
Warrants outstanding, Weighted average exercise price		$ 325.34	$ 325.34
Issued, Weighted average exercise price		0.0001
Reclassification from liability related to warrants, Weighted average exercise price		78.75
Exercised, Weighted average exercise price		0.0001
Warrants outstanding, Weighted average exercise price		120.36	325.34
Warrants exercisable, Weighted average exercise price		$ 143.32	$ 325.34
Number of warrants outstanding, beginning balance		176,429	176,429
Number of warrants issued		645,526
Number of Warrants, Reclassification From Liability Related To Warrants		497,355
Number of warrants exercised		(645,526)
Number of warrants outstanding, ending balance		673,784	176,429
Number of warrants exercisable		673,784	176,429	176,429

Capital and Other Components _5

Capital and Other Components of Equity - Summary of Warrants (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	10,562,770	1,925,929	497,355	497,355
Warrants amount	$ 1,444,058	$ 5,570,530	$ 1,641,942	$ 10,462,137
2020 Warrants
Class Of Warrant Or Right [Line Items]
Warrants amount		309,769	894,824	6,174,137
2021 Warrants
Class Of Warrant Or Right [Line Items]
Warrants amount		$ 306,704	$ 747,118	$ 4,288,000
Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	673,784	176,429	176,429	176,429
Number of warrants exercisable	673,784	176,429	176,429
Warrants amount	$ 6,117,600	$ 6,079,890
Warrants | Warrants IFF
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	57,143	57,143
Number of warrants exercisable	57,143	57,143
Warrants amount	$ 1,630,210	$ 1,630,210
Warrants | Warrants AMI
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	119,286	119,286
Number of warrants exercisable	119,286	119,286
Warrants amount	$ 4,449,680	$ 4,449,680
Warrants | 2020 Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	300,926
Number of warrants exercisable	300,926
Warrants amount	$ 19,058
Warrants | 2021 Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants outstanding	196,429
Number of warrants exercisable	196,429
Warrants amount	$ 18,652

Capital and Other Components _6

Capital and Other Components of Equity - Summary of Warrants (Parenthetical) (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 19, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Warrants IFF
Class Of Warrant Or Right [Line Items]
Number of warrants granted							57,143
Warrants exercise price							$ 420
Warrants expiring date							Nov. 07, 2024
Description of vesting requirements for share-based payment arrangement				The warrants, granted in exchange for services to be rendered by non-employees, vest proportionally to the services rendered.
Value of warrants recognized as expense during period		$ 0	$ 25,267	$ 0	$ 178,917
Warrants AMI
Class Of Warrant Or Right [Line Items]
Number of warrants granted							119,286
Warrants exercise price							$ 280
Description of vesting requirements for share-based payment arrangement				The warrants, granted in exchange for services to be rendered by non-employees, vest proportionally to the services rendered.
Value of warrants recognized as expense during period				$ 0
Warrants AMI | Warrants Expiring on October 3, 2024
Class Of Warrant Or Right [Line Items]
Number of warrants granted							85,715
Warrants expiring date							Oct. 03, 2024
Warrants AMI | Warrants Expiring on February 5, 2025
Class Of Warrant Or Right [Line Items]
Number of warrants granted							33,572
Warrants expiring date							Feb. 05, 2025
2020 Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants granted						300,926
Warrants exercise price						$ 78.75
Adjustment for warrants fair value						$ 19,058
2020 Warrants | Warrants Expiring on October 22, 2025
Class Of Warrant Or Right [Line Items]
Warrants expiring date						Oct. 22, 2025
2021 Warrants
Class Of Warrant Or Right [Line Items]
Number of warrants granted	196,429
Warrants exercise price	$ 78.75
Adjustment for warrants fair value	$ 18,652
2021 Warrants | Warrants Expiring on August 19 2026
Class Of Warrant Or Right [Line Items]
Warrants expiring date	Aug. 19, 2026

Non-controlling Interest - Summ

Non-controlling Interest - Summarized Statement of Loss and Comprehensive Loss (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Minority Interest [Line Items]
Revenue from contracts with customers	$ 11,945,092	$ 14,371,095	$ 39,668,246	$ 36,502,490
Selling, general and administrative expenses	(8,727,323)	(18,429,528)	(35,188,695)	(49,902,087)
Finance costs	(1,362,776)	(363,466)	(2,658,305)	(1,180,368)
Loss before income taxes	(495,438)	(16,804,956)	(44,275,095)	(47,750,794)
Income tax (expense) recovery	(2,013)	50	(14,543)	(11,894)
Equity holders of the Company	1,288,110	(15,009,015)	(33,893,698)	(43,029,506)
Total comprehensive loss	(728,941)	(16,472,832)	(51,014,769)	(48,147,120)
Loss attributable to the subsidiary's non-controlling interest	(1,785,561)	(1,795,891)	(10,395,940)	(4,733,182)
Comprehensive loss attributable to the subsidiary's non-controlling interest	(1,785,561)	(1,795,891)	(10,395,940)	(4,733,182)
Sprout
Minority Interest [Line Items]
Revenue from contracts with customers	8,380,966	6,791,703	24,903,038	19,456,048
Cost of sales	(7,825,211)	(7,020,841)	(23,748,469)	(19,914,902)
Selling, general and administrative expenses	(3,184,805)	(2,185,582)	(9,412,606)	(7,157,115)
Impairment loss on goodwill and intangible assets			(10,164,000)
Finance costs	(934,685)	(1,184,310)	(2,396,967)	(1,857,471)
Loss before income taxes	(3,563,735)	(3,599,030)	(20,819,004)	(9,473,440)
Income tax (expense) recovery	(14,543)	50	(14,543)	(11,894)
Equity holders of the Company	(3,578,278)	(3,598,980)	(20,833,547)	(9,485,334)
Total comprehensive loss	(3,578,278)	(3,598,980)	(20,833,547)	(9,485,334)
Loss attributable to the subsidiary's non-controlling interest	(1,785,561)	(1,803,089)	(10,395,940)	(4,752,152)
Comprehensive loss attributable to the subsidiary's non-controlling interest	$ (1,785,561)	$ (1,795,891)	$ (10,395,940)	$ (4,733,182)

Non-controlling Interest - Su_2

Non-controlling Interest - Summarized Statement of Balance Sheets (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021
Minority Interest [Line Items]
Current assets	$ 28,221,601		$ 37,388,013
Current liabilities	29,855,094		30,316,694
Total equity	15,923,853	$ 15,596,395	60,837,599	$ 94,850,120	$ 110,284,472	$ 137,545,309
Equity holders of the Company	13,597,716		48,115,522
Sprout
Minority Interest [Line Items]
Current assets	13,911,380		12,260,375
Non-current assets	28,184,381		39,000,367
Current liabilities	8,010,791		5,991,483
Non-current liabilities	34,454,862		25,362,259
Total equity	(369,892)		19,907,000
Equity holders of the Company	(2,696,029)		7,184,923
Non-controlling interest	$ 2,326,137		$ 12,722,077

Non-controlling Interest - Su_3

Non-controlling Interest - Summarized Statement of Cash Flow (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Minority Interest [Line Items]
Cash flow used in operating activities			$ (20,669,892)	$ (43,820,603)	$ (54,300,000)
Cash flow used in investment activities			2,690,035	(1,424,641)
Cash flow from financing activities			12,895,705	(978,699)
Foreign exchange loss on cash and cash equivalents held in foreign currencies			(238,166)	(454,341)
Net increase (decrease) in cash and cash equivalents			(5,322,318)	(46,678,284)
Sprout
Minority Interest [Line Items]
Cash flow used in operating activities	$ (1,873,210)	$ (531,533)	(5,798,310)	(8,605,043)
Cash flow used in investment activities		(55,519)		(56,765)
Cash flow from financing activities	1,999,408	859,130	5,249,408	8,831,765
Net increase (decrease) in cash and cash equivalents	$ 126,198	$ 272,078	$ (548,902)	$ 169,957

Share-based Payment - Additiona

Share-based Payment - Additional Information (Details)			3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 14, 2021 USD ($) shares	Jul. 08, 2019 $ / shares shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares	Mar. 31, 2021 shares	Mar. 31, 2020 Instalment	Mar. 31, 2022 USD ($) shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation recognized			$ 1,005,455	$ 1,013,795	$ 2,832,438	$ 6,251,713
Recovery of stock-based compensation			110,859	0	$ 3,263,437	$ 0
Unrecognized compensation cost weighted average remaining life					6 years 9 months 3 days	7 years 9 months 3 days
Long Term Cash Bonus
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation recognized			1,000	$ 85,468	$ 65,688	$ 238,155
Long-term incentive payable					15,000,000
Minimum market capitalization					1,000,000,000
Liability related to long-term incentive			$ 23,000		23,000				$ 88,688
Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation recognized					$ 128,680	$ 0
Number of options granted | shares			0		114,000
Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation recognized			$ 299,406	$ 162,735	$ 774,679	$ 1,598,378
Terms and conditions of share based payment					the term of the options cannot exceed ten years and every stock option granted under the stock option plan will be subject to conditions no less restrictive than a minimum vesting period of 18 months and a gradual and equal acquisition of vesting rights at least on a quarterly basis. The Company’s stock-option plan allows the Company to issue a number of stock options not exceeding 15% of the number of common shares issued and outstanding at the time of any grant. The total number of stock options issuable to a single holder cannot exceed 5% of the Company’s total issued and outstanding common shares at the time of the grant, provided that the maximum number of stock options issuable to a single consultant cannot exceed 2% of the Company's total issued and outstanding common shares at the time of the grant.
Percentage of maximum number of stock options can be issued					15%
Percentage of maximum number of stock options issuable to single holder					5%
Number of Option Issuable to Single Consultant Percentage of Outstanding Stock Maximum					2%
Vesting period					18 months
Unrecognized compensation cost			399,386	1,584,133	$ 399,386	$ 1,584,133
Unrecognized compensation cost weighted average remaining life					1 year 10 days	1 year 3 months 14 days
Non-market Performance Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation recognized			$ 0	$ 99,849	$ 0	$ 301,013
Expiration date		Jul. 08, 2029
Description of vesting requirements for share-based payment arrangement					These options vest after the attainment of non-market performance conditions within the following ten years.
Vesting period		10 years
Number of options vested | shares					0
Options exercisable | shares			0	0	0	0
Non-market Performance Options | CEO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options granted | shares		100,000
Weighted average exercise price | $ / shares		$ 4.43
Market Performance Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation recognized			$ 573,588	$ 618,162	$ 1,776,579	$ 1,863,558
Expiration date		Jul. 08, 2029
Vesting period		10 years
Options exercisable | shares			21,429	21,429	21,429	21,429
Unrecognized compensation cost			$ 9,484,197	$ 12,610,370	$ 9,484,197	$ 12,610,370
Market Performance Options | CEO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options granted | shares		157,142
Weighted average exercise price | $ / shares		$ 4.43
DSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation recognized			$ 0	$ 23,928	$ 13,025	$ 29,235
Shares outstanding | shares			4,308	4,308	4,308	4,308	1,202		4,308
Number of other equity instruments exercised or vested in share based payment arrangement upon services to be render 12 months from date of grant | shares						1,555	1,108
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation recognized			$ 132,461	$ 109,121	$ 268,155	$ 2,459,529
Loss on equity based share awards liability			110,859
Vesting period								3 years
Unrecognized compensation cost			$ 0	$ 501,720	$ 0	$ 501,720
Unrecognized compensation cost weighted average remaining life						9 months 3 days
Shares outstanding | shares			2,789	26,510	2,789	26,510	95,845		25,038
Vesting instalments | Instalment								36
Weighted average share price, Granted | $ / shares					$ 3.31
Maximum insurance coverage	$ 15,000,000
Cash entitled	$ 6,900,000
Options to purchase common stock | shares	8,500,000
Accrued liability including withholding taxes payable			$ 8,587		$ 8,587
Gain on revaluation of liability					3,263,437	$ 0
Share based compensation, settlement value			$ 132,681		$ 1,555,585
RSUs | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period							6 months
RSUs | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period							3 years

Share-based Payment - Summary o

Share-based Payment - Summary of Stock Option Plan (Details) - Stock Option Plan - $ / shares	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average exercise price, Options outstanding, Beginning balance	$ 37.41	$ 65.91
Weighted average exercise price, Granted	1.60	29.97
Weighted average exercise price, Forfeited/Cancelled	16	37.82
Weighted average exercise price, Expired	50.71	90.20
Weighted average exercise price, Options outstanding, Ending balance	18.55	45.10
Weighted average exercise price, Options exercisable	$ 39.25	$ 56.59
Options outstanding, Beginning balance	306,321	121,208
Granted	229,715	220,125
Forfeited/Cancelled	(65,361)	(86,815)
Expired	(47,033)	(7,143)
Options outstanding , Ending balance	423,642	247,375
Options exercisable	131,119	98,387

Share-based Payment - Schedule

Share-based Payment - Schedule of Number and Contractual Life of Options (Details) - Stock Option Plan	9 Months Ended
	Dec. 31, 2022 $ / shares shares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Number of options outstanding | shares	423,642
Weighted number of options exercisable | shares	131,119
$1.55 - $1.59
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range limit	$ 1.55
Exercise price, upper range limit	$ 1.59
Weighted remaining contractual life outstanding	4 years 7 months 17 days
Number of options outstanding | shares	115,715
Weighted number of options exercisable | shares	19,048
Weighted average exercise price	$ 1.55
$1.60 - $6.07
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range limit	1.60
Exercise price, upper range limit	$ 6.07
Weighted remaining contractual life outstanding	4 years 8 months 26 days
Number of options outstanding | shares	114,000
$6.08 - $27.90
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range limit	$ 6.08
Exercise price, upper range limit	$ 27.90
Weighted remaining contractual life outstanding	3 years 8 months 15 days
Number of options outstanding | shares	106,431
Weighted number of options exercisable | shares	57,621
Weighted average exercise price	$ 25.51
$27.91 - $42.96
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range limit	27.91
Exercise price, upper range limit	$ 42.96
Weighted remaining contractual life outstanding	3 years 6 months 18 days
Number of options outstanding | shares	28,669
Weighted number of options exercisable | shares	10,804
Weighted average exercise price	$ 30.23
$42.97 - $157.38
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range limit	42.97
Exercise price, upper range limit	$ 157.38
Weighted remaining contractual life outstanding	7 years 2 months 15 days
Number of options outstanding | shares	58,827
Weighted number of options exercisable | shares	43,646
Weighted average exercise price	$ 76.08

Share-based Payment - Summary_2

Share-based Payment - Summary of Assumptions Used to Determine Fair Value of Options Granted (Details) - Stock Option Plan - $ / shares	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price		$ 19.25
Risk-free interest	0.13%	0.13%
Risk-free interest	2.04%	2.04%
Estimated life (years)	3 years 6 months 14 days
Expected volatility	53.52%	53.52%
Expected volatility	91.94%	86.04%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price	$ 10.50	$ 18.20
Exercise price	10.50
Estimated life (years)		3 years 5 months 19 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share price	155.05	$ 155.05
Exercise price	$ 155.05	$ 155.05

Share-based Payment - Summary_3

Share-based Payment - Summary of Number and Weighted Average Exercise Prices of Market Performance Options (Details) - Market Performance Options - $ / shares	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average exercise price, Options outstanding, Beginning balance	$ 155.05	$ 155.05
Weighted average exercise price, Options outstanding, Ending balance	155.05	155.05
Weighted average exercise price, Options exercisable	$ 155.05	$ 155.05
Options outstanding, Beginning balance	157,142	157,142
Options outstanding , Ending balance	157,142	157,142
Options exercisable	21,429	21,429

Share-based Payment - Summary_4

Share-based Payment - Summary of Number and Weighted Average Share Prices of DSUs (Details) - DSUs - $ / shares	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average share price, Beginning balance	$ 66.45	$ 63
Weighted average share price, Ending balance	66.45	19
Weighted average share price, exercisable	$ 66.45	$ 48.18
Shares outstanding, Beginning balance	4,308	1,202
Shares outstanding, Ending balance	4,308	4,308
Shares exercisable	4,308	1,976

Share-based Payment - Summary_5

Share-based Payment - Summary of Number and Weighted Average Share Prices of RSUs (Details) - RSUs - $ / shares	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average share price, Beginning balance	$ 59.75	$ 92.08
Weighted average share price, Granted	3.31
Weighted average share price, Forfeited	19.25
Weighted average share price, Released through the issuance of common shares	5.60	155.05
Weighted average share price, Withheld as payment of withholding taxes	5.60	155.05
Weighted average share price, Ending balance	$ 60.04	$ 148.49
Shares outstanding, Beginning balance	25,038	95,845
Shares outstanding, Granted	436,449	11,751
Shares outstanding, Forfeited	(15,606)	(2,858)
Shares outstanding, Released through the issuance of common shares	(269,599)	(51,095)
Shares outstanding, Withheld as payment of withholding taxes	(173,493)	(27,133)
Shares outstanding, Ending balance	2,789	26,510

Income (Loss) per Share - Summa

Income (Loss) per Share - Summary of Earnings Per Share Basic and Diluted (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income (loss) attributed to equity holders	$ 1,288,110	$ (15,009,015)	$ (33,893,698)	$ (43,029,506)
Less: Undistributed earnings attributed to warrant holders	(631,070)
Basic net income (loss) attributed to common shareholders	657,040	(15,009,015)	(33,893,698)	(43,029,506)
Dilutive net income (loss) attributed to common shareholders	$ 657,040	$ (15,009,015)	$ (33,893,698)	$ (43,029,506)
Basic weighted-average number of common shares outstanding	11,030,838	4,781,190	8,462,761	4,765,762
Dilutive weighted-average number of common shares outstanding	11,094,967	4,781,190	8,462,761	4,765,762
Basic earnings (loss) per share	$ 0.06	$ (3.14)	$ (4.01)	$ (9.03)
Dilutive earnings (loss) per share	$ 0.06	$ (3.14)	$ (4.01)	$ (9.03)
Options, RSU's, DSU's
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Effect of dilutive securities	$ 64,129

Income (Loss) per Share - Sum_2

Income (Loss) per Share - Summary of Outstanding Securities not Included in Computation of Diluted Net Income (Loss) Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Options, RSU's, DSU's
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of outstanding securities not included in computation of diluted net income (loss) per share	523,752	435,335	587,881	435,335
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of outstanding securities not included in computation of diluted net income (loss) per share	11,236,554	673,784	11,236,554	673,784

Finance Income and Finance Cost

Finance Income and Finance Costs - Summary of Finance Income (Details) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Finance Income And Finance Costs [Abstract]
Finance income	$ 2,956	$ 1,440	$ 10,299

Finance Income and Finance Co_2

Finance Income and Finance Costs - Summary of Finance Costs (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Finance Income And Finance Costs [Abstract]
Finance costs	$ 1,362,776	$ 363,466	$ 2,658,305	$ 1,180,368

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax (Recovery) Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income tax (expense) recovery	$ 2,013	$ (50)	$ 14,543	$ 11,894

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Effective Tax Rate (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (495,438)	$ (16,804,956)	$ (44,275,095)	$ (47,750,794)
Increase (decrease) resulting from:
Total tax recovery	$ 2,013	$ (50)	$ 14,543	$ 11,894

Supplemental Cash Flow Disclosu

Supplemental Cash Flow Disclosure - Summary of Changes in Operating Assets and Liabilities (Details) - USD ($)	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Trade and other receivables	$ (2,489,793)	$ 2,541,426
Prepaid expenses	(798,493)	2,162,076
Inventories	2,544,635	2,720,569
Trade and other payables	1,599,623	2,684,869
Deferred revenues	(285,006)	(303,765)
Provisions	4,550,934	(1,112,762)
Changes in operating assets and liabilities	$ (6,543,514)	$ 6,394,409

Fair Value - Summary of Financi

Fair Value - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Liabilities
Liability related to warrants	$ 1,444,058	$ 5,570,530
Total		5,570,530
Level 3
Liabilities
Liability related to warrants	1,444,058	5,570,530
Total	$ 1,444,058	$ 5,570,530

Fair Value - Additional Informa

Fair Value - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022	Feb. 10, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Gains on re-measurement of financial assets and liabilities measured at fair value	$ 0	$ (376,753)	$ 0	$ (146,138)
Measurement of call option.	$ 0		$ 0		$ 0
Sprout Foods Inc [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Minority ownership percentage						49.90%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)			1 Months Ended	9 Months Ended	12 Months Ended
	Mar. 22, 2023	May 28, 2021	Jan. 31, 2020	Dec. 31, 2022	Mar. 31, 2022	Mar. 23, 2022
Product Liability Contingency [Line Items]
Term of minimum annual volume of sales to maintain exclusivity of specialty ingredient			8 years
Remaining amount of minimum royalties			$ 1,148,564
Arbitrator's award with fees and cost including applicable interest						$ 1,127,024
Legal proceeding provisions				$ 600,000	$ 600,000
Subsequent Event
Product Liability Contingency [Line Items]
Litigation settlement amount	$ 500,000
CEO
Product Liability Contingency [Line Items]
Percentage of royalties payable				1%
Provision				$ 606,346	$ 362,809
Moonbug Entertainment Limited | License Agreements
Product Liability Contingency [Line Items]
Minimum guaranteed payments		$ 200,000
Additional minimum guaranteed payments		$ 200,000
License agreement expiry date		Dec. 31, 2023
Agreement additional extending term		three years
Sprout Foods, Inc.
Product Liability Contingency [Line Items]
Equity interest acquired				50.10%

Operating Segments - Additional

Operating Segments - Additional Information (Details)	9 Months Ended
	Dec. 31, 2022 Segment
Segment Reporting Information [Line Items]
Number of segment	1

Operating Segments - Summary of

Operating Segments - Summary of Revenue Attributed to Geographical Locations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ 12,208,908	$ 14,667,929	$ 40,467,978	$ 37,265,069
Canada
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	1,347,700	4,560,116	7,074,759	8,920,392
United States
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	10,597,392	9,831,143	32,626,483	27,643,347
Other Countries
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue	$ 263,816	$ 276,670	$ 766,736	$ 701,330

Operating Segments - Summary _2

Operating Segments - Summary of Long-Lived Assets by Geographical Location (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Segment Reporting Information [Line Items]
Total property, plant and equipment	$ 1,862,667	$ 21,448,123
Total intangible assets	17,343,178	21,655,035
Total goodwill	14,396,380	22,168,288
Canada
Segment Reporting Information [Line Items]
Total property, plant and equipment	536,905	20,724,674
Total intangible assets	1,688,339	2,353,054
Total goodwill	2,424,414	2,625,851
United States
Segment Reporting Information [Line Items]
Total property, plant and equipment	1,325,762	723,449
Total intangible assets	15,654,839	19,301,981
Total goodwill	$ 11,971,966	$ 19,542,437

Operating Segments - Summary _3

Operating Segments - Summary of Revenue Derived from Sale of Goods (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue from sales net of excise taxes of nil and $643,476 (2021 - $746,870 and $1,127,569)	$ 11,945,092	$ 14,371,095	$ 39,668,246	$ 36,502,490
Recognized at a Point in Time | Nutraceutical Products
Disaggregation of Revenue [Line Items]
Revenue from sales net of excise taxes of nil and $643,476 (2021 - $746,870 and $1,127,569)	3,541,002	3,927,334	11,844,529	11,168,555
Recognized at a Point in Time | Cannabis and Hemp Products
Disaggregation of Revenue [Line Items]
Revenue from sales net of excise taxes of nil and $643,476 (2021 - $746,870 and $1,127,569)	23,337	3,516,488	2,740,664	5,659,039
Recognized at a Point in Time | Food and Beverage Products
Disaggregation of Revenue [Line Items]
Revenue from sales net of excise taxes of nil and $643,476 (2021 - $746,870 and $1,127,569)	$ 8,380,753	6,927,617	$ 25,083,053	19,606,381
Recognized at a Point in Time | Innovation Products
Disaggregation of Revenue [Line Items]
Revenue from sales net of excise taxes of nil and $643,476 (2021 - $746,870 and $1,127,569)		$ (344)		$ 68,515

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Royalty Expense	$ 0	$ 0	$ 0	$ 0

Subsequent Events (Additional I

Subsequent Events (Additional Information) (Details) - USD ($)						9 Months Ended
	May 15, 2023	Mar. 31, 2023	Mar. 09, 2023	Jan. 25, 2023	Jan. 13, 2023	Dec. 31, 2022	Oct. 11, 2022	Aug. 31, 2022
Subsequent Event [Line Items]
Warrants issued during the period						10,308,166
Exercise price						$ 3.10	$ 1.62	$ 2.32
Scenario Forecast | Waiver Agreement
Subsequent Event [Line Items]
Exit fee paid by purchaser	$ 100,000	$ 100,000
Subsequent Event
Subsequent Event [Line Items]
Gross proceeds from Senir secured notes financing					$ 4,000,000
Senior secured notes financing, Description					The Notes will mature 12 months from the initial closing and bear interest at a rate of 16.5% per annum.
Senior secured notes financing, Interest rate			24%		16.50%
Senior secured notes financing, Payment term					Interest will be payable in kind on the first 6 monthly payment dates after the initial closing date and thereafter will be payable in cash.
Warrants issued during the period					850,000
Warrant Exercisable Term					5 years
Exercise price					$ 0.53
Subsequent Event | Waiver Agreement
Subsequent Event [Line Items]
Exit fee paid by purchaser			$ 200,000
Subsequent Event | Sprout Organics | Alterna
Subsequent Event [Line Items]
Accounts receivable factoring facility, Maximum amount available				$ 5,000,000
Fund usage fees, Percentage				1%
Accounts receivable factoring facility, Interest rate payable				8%
Accounts receivable factoring facility, Agreement terms				The agreement will remain in effect for a 12-month period, effective January 23, 2023, and will be automatically renewed.